<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">13783</article-id><article-id pub-id-type="doi">10.7554/eLife.13783</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biophysics and Structural Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology</subject></subj-group></article-categories><title-group><article-title>Structural basis for germline antibody recognition of HIV-1 immunogens</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-48454"><name><surname>Scharf</surname><given-names>Louise</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa1">†</xref></contrib><contrib contrib-type="author" id="author-48455"><name><surname>West</surname><given-names>Anthony P</given-names><suffix>Jr</suffix></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-48456"><name><surname>Sievers</surname><given-names>Stuart A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa2">‡</xref></contrib><contrib contrib-type="author" id="author-48457"><name><surname>Chen</surname><given-names>Courtney</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-48458"><name><surname>Jiang</surname><given-names>Siduo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa3">§</xref></contrib><contrib contrib-type="author" id="author-48459"><name><surname>Gao</surname><given-names>Han</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-48460"><name><surname>Gray</surname><given-names>Matthew D</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-48461"><name><surname>McGuire</surname><given-names>Andrew T</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-48462"><name><surname>Scheid</surname><given-names>Johannes F</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-1153"><name><surname>Nussenzweig</surname><given-names>Michel C</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-48464"><name><surname>Stamatatos</surname><given-names>Leonidas</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-39433"><name><surname>Bjorkman</surname><given-names>Pamela J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Division of Biology and Biological Engineering</institution>, <institution>California Institute of Technology</institution>, <addr-line><named-content content-type="city">Pasadena</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Vaccine and Infectious Disease Division</institution>, <institution>Fred Hutchinson Cancer Research Center</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Laboratory of Molecular Immunology</institution>, <institution>The Rockefeller University</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><label>4</label><institution>Howard Hughes Medical Institute, The Rockefeller University</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Chakraborty</surname><given-names>Arup K</given-names></name><role>Reviewing editor</role><aff id="aff5"><institution>Massachusetts Institute of Technology</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><email>bjorkman@caltech.edu</email></corresp><fn fn-type="present-address" id="pa1"><label>†</label><p>23andMe, Mountain View, United States</p></fn><fn fn-type="present-address" id="pa2"><label>‡</label><p>Kite Pharma, Santa Monica, United States</p></fn><fn fn-type="present-address" id="pa3"><label>§</label><p>D. E. Shaw Research, New York, United States</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>21</day><month>03</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>5</volume><elocation-id>e13783</elocation-id><history><date date-type="received"><day>14</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>05</day><month>03</month><year>2016</year></date></history><permissions><copyright-statement>© 2016, Scharf et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Scharf et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-13783-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.13783.001</object-id><p>Efforts to elicit broadly neutralizing antibodies (bNAbs) against HIV-1 require understanding germline bNAb recognition of HIV-1 envelope glycoprotein (Env). The VRC01-class bNAb family derived from the VH1-2*02 germline allele arose in multiple HIV-1–infected donors, yet targets the CD4-binding site on Env with common interactions. Modified forms of the 426c Env that activate germline-reverted B cell receptors are candidate immunogens for eliciting VRC01-class bNAbs. We present structures of germline-reverted VRC01-class bNAbs alone and complexed with 426c-based gp120 immunogens. Germline bNAb–426c gp120 complexes showed preservation of VRC01-class signature residues and gp120 contacts, but detectably different binding modes compared to mature bNAb-gp120 complexes. Unlike typical antibody-antigen interactions, VRC01–class germline antibodies exhibited preformed antigen-binding conformations for recognizing immunogens. Affinity maturation introduced substitutions increasing induced-fit recognition and electropositivity, potentially to accommodate negatively-charged complex-type <italic>N</italic>-glycans on gp120. These results provide general principles relevant to the unusual evolution of VRC01–class bNAbs and guidelines for structure-based immunogen design.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.13783.001">http://dx.doi.org/10.7554/eLife.13783.001</ext-link></p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.13783.002</object-id><title>eLife digest</title><p>When human immunodeficiency virus-1 (HIV-1) infects humans it can cause a serious disease that damages the immune system. Currently there is no cure for this disease and there are no vaccines available to halt the spread of the virus. Researchers are hoping to be able to develop a single vaccine that can protect individuals against every form (or strain) of HIV-1, but this has proved difficult because many different versions of the virus exist.</p><p>An effective vaccine triggers long-lasting immunity to a particular virus or microbe by activating the production of proteins called antibodies that identify and help to destroy the threat. Research has shown that most individuals infected with HIV-1 produce antibodies that can only recognize a few HIV strains. However, there are rare individuals who produce “broadly neutralizing antibodies”; that is, antibodies that can recognize and help to kill 90% or more of HIV-1 strains. Understanding how broadly neutralizing antibodies are produced in infected individuals may aid the development of a vaccine that can protect others from the many circulating strains of HIV.</p><p>When an individual encounters a virus, immature antibodies are modified to generate mature antibodies that bind more effectively to specific virus proteins. Here, Scharf et al. investigated how a class of broadly neutralizing antibodies called VRC01-class antibodies, which bind to an HIV protein called gp120, are produced. The experiments used a technique called X-ray crystallography to reveal the three-dimensional structures of immature versions of these antibodies when they are bound to gp120.</p><p>Scharf et al. discovered that, unlike most antibodies, the overall final structure of VRC01 antibodies is formed before the antibody matures. Instead of making large changes to the structure of these antibodies, the maturation process makes VRC01-class antibodies become more positively charged, which allows them to bind to gp120 proteins on a wider variety of HIV viruses. These findings suggest that it may be possible to use modified gp120 proteins in vaccines to trigger the production of broadly neutralizing antibodies against HIV.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.13783.002">http://dx.doi.org/10.7554/eLife.13783.002</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>HIV</kwd><kwd>broadly neutralizing antibodies</kwd><kwd>crystallography</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research Organism</title><kwd>Human</kwd><kwd>Virus</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AI100148</award-id><principal-award-recipient><name><surname>Nussenzweig</surname><given-names>Michel C</given-names></name><name><surname>Bjorkman</surname><given-names>Pamela J</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000865</institution-id><institution>Bill and Melinda Gates Foundation</institution></institution-wrap></funding-source><award-id>1040753</award-id><principal-award-recipient><name><surname>Bjorkman</surname><given-names>Pamela J</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000048</institution-id><institution>American Cancer Society</institution></institution-wrap></funding-source><award-id>PF-13-076-01-MPC</award-id><principal-award-recipient><name><surname>Scharf</surname><given-names>Louise</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005192</institution-id><institution>California HIV/AIDS Research Program</institution></institution-wrap></funding-source><award-id>F12-CT-214</award-id><principal-award-recipient><name><surname>Sievers</surname><given-names>Stuart A</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000865</institution-id><institution>Bill and Melinda Gates Foundation</institution></institution-wrap></funding-source><award-id>1124068</award-id><principal-award-recipient><name><surname>Nussenzweig</surname><given-names>Michel C</given-names></name></principal-award-recipient></award-group><funding-statement>The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Bill and Melinda Gates Foundation, ACS or CHRP.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Structural and computational analyses of germline antibody/HIV-1 gp120 complexes provide both general principles relevant to the unusual evolution of potent CD4-binding site antibodies and guidelines for structure-based immunogen design.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The HIV-1 envelope (Env) spike, a trimer of gp120-gp41 heterodimers, is the only target of neutralizing antibodies (Abs). Rapid mutation combined with structural features of the Env trimer that hide conserved features of the HIV-1 spike result in induction of mainly strain-specific neutralizing Abs in most infected individuals. However, broadly neutralizing Abs (bNAbs) evolve in a minority of HIV-1–infected individuals after several years of infection. These Abs are of considerable interest for HIV-1 therapeutic efforts because they can prevent and treat infection in animal models (reviewed in ([<xref ref-type="bibr" rid="bib49">West et al., 2014</xref>]) and exhibited efficacy against HIV-1 in a human clinical trial (<xref ref-type="bibr" rid="bib7">Caskey et al., 2015</xref>). Thus, it is believed that an immunogen that could elicit bNAbs would induce a protective immune response against infection by HIV-1.</p><p>Highly potent bNAbs against the conserved CD4-binding site (CD4bs) on gp120 that were derived from the VH1-2*02 variable heavy chain (HC) gene have been isolated from at least nine HIV-1–infected individuals (<xref ref-type="bibr" rid="bib41">Scheid et al., 2011</xref>; <xref ref-type="bibr" rid="bib50">Wu et al., 2010</xref>; <xref ref-type="bibr" rid="bib53">Zhou et al., 2013</xref>; <xref ref-type="bibr" rid="bib54">2015</xref>; <xref ref-type="bibr" rid="bib51">Wu et al., 2011</xref>; <xref ref-type="bibr" rid="bib17">Georgiev et al., 2013</xref>). These bNAbs exhibit unusually high levels of somatic hypermutation, with changes in both complementarity determining regions (CDRs) and framework regions (FWRs) (<xref ref-type="bibr" rid="bib23">Klein et al., 2013</xref>). As exemplified by VRC01, the first such bNAb to be isolated (<xref ref-type="bibr" rid="bib50">Wu et al., 2010</xref>), VRC01-class bNAbs share a common mode of gp120 binding in which the VH1-2*02-derived variable heavy (V<sub>H</sub>) domain mimics CD4 (<xref ref-type="bibr" rid="bib50">Wu et al., 2010</xref>; <xref ref-type="bibr" rid="bib52">Zhou et al., 2010</xref>; <xref ref-type="bibr" rid="bib53">2013</xref>; <xref ref-type="bibr" rid="bib54">2015</xref>; <xref ref-type="bibr" rid="bib8">Diskin et al., 2011</xref>). Signature features of the HCs of VRC01-class bNAbs that explain their derivation from the VH1-02*02 gene segment include Trp50<sub>HC</sub>, Asn58<sub>HC</sub>, and Arg71<sub>HC</sub>; an additional signature residue, Trp100B<sub>HC</sub> within CDRH3, is derived from the joining of the D and J gene segments to the VH gene segment during V(D)J recombination (<xref ref-type="bibr" rid="bib48">Diskin et al., 2012</xref>). The variable light (V<sub>L</sub>) domains of VRC01-class bNAbs, which can be derived from several different VL germline gene segments, require a short (five residues) CDRL3 loop to allow interactions with gp120 V5 and loop D (<xref ref-type="bibr" rid="bib48">Diskin et al., 2012</xref>) and often include a deletion in CDRL1 to avoid clashes with an <italic>N</italic>-linked glycan attached to Asn276<sub>gp120</sub> (<xref ref-type="bibr" rid="bib52">Zhou et al., 2010</xref>; <xref ref-type="bibr" rid="bib53">2013</xref>; <xref ref-type="bibr" rid="bib40">Scharf et al., 2013</xref>). The LC contact residues of VRC01-like bNAbs and the short CDRL3 are not germline encoded (<xref ref-type="bibr" rid="bib48">Diskin et al., 2012</xref>). Because VRC01-class bNAbs are highly potent, have demonstrated efficacy in animal and human trials, and evolved in multiple HIV-1–infected donors who were infected with different strains of HIV-1, they are considered a promising target for elicitation by vaccination with designed immunogens.</p><p>The first step in eliciting an Ab is binding to its precursor germline-encoded B cell receptor by an antigen or immunogen with adequate affinity to initiate B cell activation and affinity maturation (<xref ref-type="bibr" rid="bib2">Batista and Neuberger, 1998</xref>). Although the unmutated VH1-2*02 gene segment includes the signature V<sub>H</sub> domain residues for interacting with the CD4bs, germline-reverted versions of VRC01-class bNAbs do not bind to Env trimers or to gp120 (<xref ref-type="bibr" rid="bib41">Scheid et al., 2011</xref>; <xref ref-type="bibr" rid="bib52">Zhou et al., 2010</xref>; <xref ref-type="bibr" rid="bib48">Diskin et al., 2012</xref>; <xref ref-type="bibr" rid="bib40">Scharf et al., 2013</xref>; <xref ref-type="bibr" rid="bib19">Hoot et al., 2013</xref>; <xref ref-type="bibr" rid="bib48">Ota et al., 2012</xref>; <xref ref-type="bibr" rid="bib31">McGuire et al., 2013</xref>). In previous studies, we investigated VRC01-class germline recognition of Env by solving a crystal structure of the clade A/E 93TH057 gp120 core bound to a half germline, half mature chimeric VRC01-class Ab (NIH45-46<sub>CHIM</sub>) in which the inferred germline HC was paired with the mature LC to permit binding to an unmodified gp120 (<xref ref-type="bibr" rid="bib40">Scharf et al., 2013</xref>). Two forms of designed gp120-based immunogens were subsequently engineered to bind and activate germline HC/LC VRC01-class B cell receptors: gp120 outer domain-only constructs (eOD-GT6 and eOD-GT8) (<xref ref-type="bibr" rid="bib20">Jardine et al., 2013</xref>; <xref ref-type="bibr" rid="bib21">2015</xref>) and gp120s modified from the clade C 426c Env (<xref ref-type="bibr" rid="bib31">McGuire et al., 2013</xref>; <xref ref-type="bibr" rid="bib32">2014</xref>; <xref ref-type="bibr" rid="bib33">2016</xref>). Crystal structures of the inferred germline Fab of VRC01 complexed with eOD-GT6 and NIH45-46<sub>CHIM</sub> complexed with gp120 revealed a similar angle of approach for binding as mature Fabs and conservation of the signature VRC01-class interactions with gp120 residues (<xref ref-type="bibr" rid="bib40">Scharf et al., 2013</xref>; <xref ref-type="bibr" rid="bib20">Jardine et al., 2013</xref>). However, questions concerning germline B-cell receptor recognition of gp120 remained because neither structure represented a complex between a fully germline VRC01-class Ab and a complete gp120 core. Here, we present crystal structures of inferred germline VRC01-like Abs alone and complexed with 426c-based gp120 immunogen cores and compare and contrast their gp120 recognition with structures of mature VRC01-class Ab/gp120 complexes. The analyses shed insight on the evolution pathway by which Abs derived from VH1-2*02 germline mature towards broad recognition of the CD4bs on gp120 and provide structural information that will facilitate design of immunogens to elicit VRC01-class bNAbs.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Expression and characterization of germline and mature VRC01-class Abs</title><p>The antigen-binding Fabs of two VRC01-class Abs isolated from different patients, NIH45-46 and 3BNC60 (<xref ref-type="bibr" rid="bib41">Scheid et al., 2011</xref>), were generated in their inferred germline forms (NIH45-46<sub>GL</sub> and 3BNC60<sub>GL</sub>) using sequences described in previous studies (<xref ref-type="bibr" rid="bib40">Scharf et al., 2013</xref>; <xref ref-type="bibr" rid="bib19">Hoot et al., 2013</xref>; <xref ref-type="bibr" rid="bib31">McGuire et al., 2013</xref>; <xref ref-type="bibr" rid="bib11">Dosenovic et al., 2015</xref>). Compared with mature NIH45-46 (NIH45-46<sub>MAT</sub>), NIH45-46<sub>GL</sub> contained 40 HC and 23 LC substitutions in addition to a two-residue insertion in CDRL1. 3BNC60<sub>GL</sub> contained 38 HC and 25 LC substitutions in addition to a four-residue deletion in HC framework region 3 (FWR3<sub>HC</sub>) and a four-residue insertion in CDRL1 compared with 3BNC60<sub>MAT</sub> (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Two versions of germline-binding gp120s were expressed as gp120 cores with N/C termini and V1-V2 and V3 loop truncations (<xref ref-type="bibr" rid="bib52">Zhou et al., 2010</xref>): (<italic>i</italic>) 426c.NLGS.TM1△V1-3 (hereafter referred to as 426c.TM1△V1-3), a modified version of the clade C 426c Env in which the V1, V2 and V3 loops were truncated and three potential <italic>N</italic>-linked glycosylation sites at gp120 residues Asn276<sub>gp120</sub>, Asn460<sub>gp120</sub> and Asn463<sub>gp120</sub> were removed by mutation (N276D, N460D, and N463D) (<xref ref-type="bibr" rid="bib31">McGuire et al., 2013</xref>; <xref ref-type="bibr" rid="bib32">2014</xref>), and (<italic>ii</italic>) 426c.TM4△V1-3, a modification of 426c.TM1△V1-3 with additional substitutions (D276N, S278R, G471S) (<xref ref-type="bibr" rid="bib33">McGuire et al., 2016</xref>; <xref ref-type="bibr" rid="bib11">Dosenovic et al., 2015</xref>). 426c.TM1△V1-3 binds to germline VRC01 and NIH45-46 (<xref ref-type="bibr" rid="bib31">McGuire et al., 2013</xref>; <xref ref-type="bibr" rid="bib32">2014</xref>), and 426c.TM4△V1-3 binds to germline versions of 12A21, 3BNC60, VRC-CH31, VRC-PG19 and VRC-PG20 in addition to germline VRC01 and NIH45-46 (<xref ref-type="bibr" rid="bib33">McGuire et al., 2016</xref>).<fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.13783.003</object-id><label>Figure 1.</label><caption><title>Sequence Alignments of Inferred Germline and Mature Forms of 3BNC60 and NIH45-46.</title><p>Alignments of (<bold>A</bold>) V<sub>H</sub> and (<bold>B</bold>) V<sub>L</sub> sequences of inferred germline progenitors (3BNC60<sub>GL</sub> and NIH45-46<sub>GL</sub>), mature 3BNC60 (3BNC60<sub>MAT</sub>), mature NIH45-46 (NIH45-46<sub>MAT</sub>), and the predicted germline V gene segments from which they were derived. Antibody framework regions (FWR) and CDR loops (CDR) are marked and CDR loops are colored blue (CDR1), green (CDR2), and red (CDR3). CDR3 sequences for germline Fabs were taken from mature antibody sequences as done in previous studies (<xref ref-type="bibr" rid="bib11">Dosenovic et al., 2015</xref>; <xref ref-type="bibr" rid="bib19">Hoot et al., 2013</xref>; <xref ref-type="bibr" rid="bib31">McGuire et al., 2013</xref>; <xref ref-type="bibr" rid="bib40">Scharf et al., 2013</xref>).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.13783.003">http://dx.doi.org/10.7554/eLife.13783.003</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-13783-fig1-v1"/></fig></p><p>We used a surface plasmon resonance (SPR)-based assay to compare the binding of NIH45-46<sub>GL</sub>, 3BNC60<sub>GL</sub>, NIH45-46<sub>MAT</sub>, and 3BNC60<sub>MAT</sub> to gp120 cores including the 426c immunogens and a representative gp120 (93TH057) used for structural studies with mature bNAbs (<xref ref-type="fig" rid="fig2">Figure 2</xref>). As expected, the germline-reverted Abs did not bind detectably to 93TH057 gp120, but NIH45-46<sub>GL </sub>bound to both 426c.TM1ΔV1-3 and 426c.TM4ΔV1-3 gp120s with equilibrium dissociation constants (<italic>K</italic><sub>D</sub>s) of ~0.7 and 3 μM, respectively. As previously described (<xref ref-type="bibr" rid="bib31">McGuire et al., 2013</xref>; <xref ref-type="bibr" rid="bib32">2014</xref>), 3BNC60<sub>GL</sub> did not bind to 426c.TM1ΔV1-3, but showed detectable binding to 426c.TM4ΔV1-3 gp120. By contrast, NIH45-46<sub>MAT</sub> and 3BNC60<sub>MAT</sub> bound to all gp120s with nM or higher affinity (<xref ref-type="fig" rid="fig2">Figure 2</xref>).<fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.13783.004</object-id><label>Figure 2.</label><caption><title>SPR binding assays.</title><p>Representative sensograms (red), fits (black, where applicable), residuals, and <italic>K</italic><sub>D</sub>, <italic>k</italic><sub>a</sub>, and <italic>k</italic><sub>d</sub> values (mean ± standard deviation from 3 independent experiments) for binding of germline and mature Abs to gp120 cores. NIH45-46<sub>GL</sub>, 3BNC60<sub>GL</sub>, NIH45-46<sub>MAT</sub> and 3BNC60<sub>MAT</sub> IgG were captured on a protein A biosensor chip, and 426c.TM1△V1-3, 426c.TM4△V1-3 and 93TH057 gp120 cores were flowed over the chip as a 2-fold dilution series with top concentrations of 16 mM and 400 nM for germline and mature Abs, respectively.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.13783.004">http://dx.doi.org/10.7554/eLife.13783.004</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-13783-fig2-v1"/></fig></p><p>Crystal structures of NIH45-46<sub>GL</sub> bound to 426c.TM1△V1-3 and 3BNC60<sub>GL</sub> bound to 426c.TM4△V1-3 were solved to 3.4 Å and 3.1 Å resolution, respectively (<xref ref-type="table" rid="tbl1">Table 1</xref>). We also solved structures of unbound 3BNC60<sub>GL</sub> and 426c.TM4△V1-3 (at 1.9 Å and 2.0 Å resolution, respectively), and a complex structure of a 426c.TM4△V1-3 bound to 3BNC55<sub>MAT</sub>, a mature VRC01-class Ab (<xref ref-type="table" rid="tbl1">Table 1</xref>). We compared the new structures to previously-reported complex structures of NIH45-46<sub>CHIM</sub>/93TH057 gp120 and VRC01<sub>GL</sub>/eOD-GT6 (PDB codes 4JDT and 4JPK), unbound structures of NIH45-46<sub>GL</sub> and VRC01<sub>GL</sub> (PDB codes 4JDV and 4JPI) (<xref ref-type="bibr" rid="bib40">Scharf et al., 2013</xref>; <xref ref-type="bibr" rid="bib20">Jardine et al., 2013</xref>), and representative mature VRC01-class Fab/gp120 complexes; e.g., NIH45-46<sub>MAT</sub>/93TH057 gp120 and 3BNC117<sub>MAT</sub>/93TH057 gp120 (PDB codes 3U7Y and 4JPV) (<xref ref-type="bibr" rid="bib53">Zhou et al., 2013</xref>; <xref ref-type="bibr" rid="bib8">Diskin et al., 2011</xref>).<table-wrap id="tbl1" position="float"><object-id pub-id-type="doi">10.7554/eLife.13783.005</object-id><label>Table 1.</label><caption><p>Data collection and refinement statistics, molecular replacement.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.13783.005">http://dx.doi.org/10.7554/eLife.13783.005</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>3BNC60<sub>GL</sub> Fab (5F7E)</th><th>426c.TM4ΔV1-3 (5FA2)</th><th>3BNC60<sub>GL</sub> Fab-426c.TM4ΔV1-3 complex (5FEC)</th><th>NIH45-46<sub>GL</sub> Fab-426c.TM1ΔV1-3 complex (5IGX)</th><th>3BNC55<sub>MAT</sub> Fab-426c.TM4ΔV1-3 complex (5I9Q)</th></tr></thead><tbody><tr><td>Resolution range</td><td>34.13 - 1.9 (1.97 - 1.9)</td><td>35.8 - 2.0 (2.072 - 2.0)</td><td>37.44 - 3.1 (3.211 - 3.1)</td><td>39.37 - 3.4 (3.521 - 3.4)</td><td>37.54 - 2.8 (3.10 - 3.0)</td></tr><tr><td>Space group</td><td>P2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td>C121</td><td>P2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td>F222</td><td>P3<sub>1</sub>21</td></tr><tr><td>Unit cell dimensions</td><td/><td/><td/><td/><td/></tr><tr><td><italic>a, b, c</italic> (Å)</td><td>74.9, 74.9, 83.1</td><td>144.9, 85.9, 90.0</td><td>103.1, 134.1, 195.0</td><td>147.1, 169.3, 177.7</td><td>122.9, 122.9, 265.0</td></tr><tr><td>α, β, γ (°)</td><td>90.0, 90.0, 90.0</td><td>90.0, 104.8, 90.0</td><td>90.0, 90.0, 90.0</td><td>90.0, 90.0, 90.0</td><td>90.0, 90.0, 120.0</td></tr><tr><td>Total reflections</td><td>243498 (23377)</td><td>416316 (24886)</td><td>335536 (34539)</td><td>207967 (20780)</td><td>710649 (51477)</td></tr><tr><td>Unique reflections</td><td>37256 (3651)</td><td>81715 (7961)</td><td>49653 (4885)</td><td>15410 (1508)</td><td>57299 (4353)</td></tr><tr><td>Multiplicity</td><td>6.5 (6.5)</td><td>4.6 (4.5)</td><td>6.1 (6.4)</td><td>13.5 (13.8)</td><td>12.4 (11.8)</td></tr><tr><td>Completeness (%)</td><td>0.95 (0.98)</td><td>0.97 (0.95)</td><td>1.00 (1.00)</td><td>1.00 (1.00)</td><td>0.71 (95.7)</td></tr><tr><td>Mean I/sigma(I)</td><td>16.56 (2.36)</td><td>13.35 (0.6)</td><td>9.75 (1.47)</td><td>21.76 (4.03)</td><td>8.65 (1.3)</td></tr><tr><td>Wilson B-factor</td><td>23.2</td><td>30.3</td><td>68.98</td><td>97.44</td><td>77.46</td></tr><tr><td>R-merge</td><td>0.09029 (0.8891)</td><td>0.06624 (1.36)</td><td>0.1729 (1.305)</td><td>0.1087 (0.6832)</td><td>0.327 (3.774)</td></tr><tr><td>CC1/2</td><td>0.999 (0.831)</td><td>0.999 (0.437)</td><td>0.995 (0.483)</td><td>0.999 (0.909)</td><td>0.993 (0.186)</td></tr><tr><td>CC*</td><td>1 (0.953)</td><td>1 (0.78)</td><td>0.999 (0.807)</td><td>1 (0.976)</td><td>0.998 (0.56)</td></tr><tr><td>R<sub>work</sub></td><td>0.196</td><td>0.207</td><td>0.203</td><td>0.279</td><td>0.240</td></tr><tr><td>R<sub>free</sub></td><td>0.210</td><td>0.232</td><td>0.267</td><td>0.286</td><td>0.279</td></tr><tr><td><italic>Number of atoms</italic></td><td>3502</td><td>5860</td><td>16611</td><td>5061</td><td>11572</td></tr><tr><td>macromolecules</td><td>3226</td><td>5124</td><td>16198</td><td>4956</td><td>11258</td></tr><tr><td>ligands</td><td/><td>320</td><td>413</td><td>105</td><td>314</td></tr><tr><td>Protein residues</td><td>429</td><td>672</td><td>2182</td><td>697</td><td>1537</td></tr><tr><td>RMS (bonds)</td><td>0.01</td><td>0.012</td><td>0.014</td><td>0.017</td><td>0.014</td></tr><tr><td>RMS (angles)</td><td>1.28</td><td>1.534</td><td>1.22</td><td>1.75</td><td>1.35</td></tr><tr><td>Clashscore</td><td>4.93</td><td>6.6</td><td>15.17</td><td>9.77</td><td>28.65</td></tr><tr><td><italic>Average B-factor</italic></td><td>33.0</td><td>48.66</td><td>84.92</td><td>95.14</td><td>86.29</td></tr><tr><td>macromolecules</td><td>31.14</td><td>47.27</td><td>83.94</td><td>93.81</td><td>86.98</td></tr><tr><td>ligands</td><td/><td>70.79</td><td>123.27</td><td>165.32</td><td>61.48</td></tr><tr><td>solvent</td><td>38.67</td><td>48.77</td><td/><td/><td/></tr><tr><td/><td/><td/><td/><td/><td/></tr><tr><td colspan="4">Statistics for the highest-resolution shell are shown in parentheses. <break/><break/></td><td/><td/></tr></tbody></table></table-wrap></p></sec><sec id="s2-2"><title>Germline Abs exhibit preformed antigen-binding conformations</title><p>To evaluate the structural plasticity of the inferred germline versions of the VRC01-class bNAbs, we superimposed available structures of inferred germline Fabs in their free and antigen-complexed forms. Superimpositions of bound and unbound forms of NIH45-46<sub>GL</sub> and 3BNC60<sub>GL</sub> Fabs (this study) and bound and unbound VRC01<sub>GL</sub> (<xref ref-type="bibr" rid="bib20">Jardine et al., 2013</xref>) revealed no major structural changes (<xref ref-type="fig" rid="fig3">Figure 3A,C,E</xref>). We previously noted slight differences between bound and unbound NIH45-46<sub>MAT</sub> in the conformations of CDRs L1 and H3 and positions of the Tyr89<sub>CDRL3</sub> and Tyr74<sub>FWRH3</sub> side chains (<xref ref-type="fig" rid="fig3">Figure 3G</xref>) (<xref ref-type="bibr" rid="bib8">Diskin et al., 2011</xref>), but the counterpart residues in NIH45-46<sub>GL</sub> were not affected by gp120 binding (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). In addition, superimpositions of bound and unbound 3BNC60<sub>GL</sub> Fab showed no major structural changes except in CDRL1, which either flipped the backbone conformation of the Asp28<sub>LC</sub>-Asn31<sub>LC</sub> segment (in the case of one Fab/gp120 complex in the crystallographic asymmetric unit; <xref ref-type="fig" rid="fig3">Figure 3H</xref>) or was partially disordered (in the case of the second Fab/gp120 complex in the asymmetric unit), thus avoiding clashes with loop D of gp120 despite a four-residue insertion in CDRL1. In the mature Ab 3BNC60<sub>MAT</sub> (and presumably its close relative 3BNC117<sub>MAT</sub>), a disrupted β-strand in the region of Pro61<sub>HC</sub> was reordered upon binding to gp120 (<xref ref-type="bibr" rid="bib23">Klein et al., 2013</xref>), but no notable differences in the bound and free forms of 3BNC60<sub>GL</sub> were seen in the counterpart region, which contained Ala61<sub>HC</sub> instead of Pro61<sub>HC</sub> (<xref ref-type="fig" rid="fig3">Figure 3H,I</xref>). Root mean square deviations (rmsds) for superimposing all Cα atoms in the V<sub>H</sub>V<sub>L</sub> domains of bound and unbound Fabs of NIH45-46<sub>GL</sub>, 3BNC60<sub>GL</sub>, and VRC01<sub>GL</sub> were low (0.54 Å–0.73 Å) (<xref ref-type="fig" rid="fig3">Figure 3K</xref>). Thus the association of the V<sub>H</sub> and V<sub>L</sub> domains and the conformations of the CDR loops and surrounding FWRs found in the unbound forms were largely maintained in the germline-inferred Abs upon binding to their antigens.<fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.13783.006</object-id><label>Figure 3.</label><caption><title>Overview of Bound and Unbound Structures of Germline and Mature Forms of NIH45-46 and 3BNC60.</title><p>Superposition of unbound (grey) and bound (colored) Fab structures of (<bold>A</bold>) NIH45-46<sub>GL</sub> (blue), (<bold>B</bold>) NIH45-46<sub>MAT</sub> (orange), (<bold>C</bold>) 3BNC60<sub>GL</sub> (green), (<bold>D</bold>) 3BNC60<sub>MAT</sub> (purple), and (<bold>E</bold>) VRC01<sub>GL</sub> (teal). The crystal structures were superimposed on their V<sub>H</sub>V<sub>L</sub> domains and are shown as wire representations with CDR loops colored blue (CDR1), green (CDR2), and red (CDR3). Panels (<bold>F</bold>–<bold>I</bold>) show detailed areas of interest for the corresponding structure comparisons shown in panels (<bold>A</bold>–<bold>D</bold>). Protein backbones are shown as wire diagrams, side chains are shown as stick representations (red, oxygen; blue, nitrogen). (<bold>J</bold>) Superposition of unbound (grey) and bound (red) structures of 426c.TM4△V1-3 shown as wire diagrams. (<bold>K</bold>) Table summarizing Cα rmsds for the indicated Ab and gp120 pairs. Since no unbound crystal structure of 3BNC117<sub>MAT</sub> was available, the structure of the close clonal relative, 3BNC60<sub>MAT</sub> (93%HC/96% LC sequence identity) was substituted. Similarly, no unbound structure of VRC01<sub>MAT</sub> was available, so that of NIH45-46<sub>MAT</sub> (88%HC/96% LC sequence identity) was substituted, omitting its four-residue insertion in CDRH3 from the rmsd calculation.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.13783.006">http://dx.doi.org/10.7554/eLife.13783.006</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-13783-fig3-v1"/></fig></p><p>Superpositions of bound and unbound forms of the mature counterparts of these bNAbs (using a closely-related unbound Fab structure when necessary) also revealed relatively small rmsd values with the exception of the 1.66 Å rmsd when comparing free 3BNC60<sub>MAT</sub> and complexed 3BNC117<sub>MAT</sub> due to the disrupted β-sheet structure near Pro61<sub>HC</sub> of free 3BNC60<sub>MAT</sub> (<xref ref-type="fig" rid="fig3">Figure 3I</xref>) (<xref ref-type="bibr" rid="bib23">Klein et al., 2013</xref>) – when the disrupted β-strand was excluded, the rmsd dropped to 0.72 Å (<xref ref-type="fig" rid="fig3">Figure 3K</xref>). Thus the mature bNAbs (NIH45-46<sub>MAT</sub>, 3BNC60<sub>MAT</sub>, and VRC01<sub>MAT</sub>) are overall largely preformed to recognize antigen, but exhibited more antigen binding-induced conformational flexibility within individual CDR loops and/or the FWRs than the germline-inferred Abs.</p><p>We addressed potential changes in antigen structure resulting from germline and mature Ab binding by comparing structures of free and bound 426c.TM4△1–3 gp120 core. The 426c.TM4△1–3 structure was solved using crystals of the gp120 core alone and again as part of the analysis of the 3BNC60<sub>GL</sub>/426c.TM4△V1-3 crystals in which the crystallographic asymmetric unit included two copies of unbound 426c.TM4△V1-3 gp120 along with two copies of the 3BNC60<sub>GL</sub>/426c.TM4△V1-3 complex. We compared the unbound 426c.TM4△V1-3 structures to those of 426c.TM4△V1-3 complexed with Fabs from 3BNC60<sub>GL</sub> and from a mature VRC01-class Ab, 3BNC55<sub>MAT</sub>. We found no major structural rearrangements resulting from binding of either a germline or mature Ab (<xref ref-type="fig" rid="fig3">Figure 3J,K</xref>), suggesting that the 426c gp120 core immunogens are preformed for binding to germline and mature forms of VRC01-class Abs. Since these immunogens lack the V1V2 and V3 loops, potential rearrangement of these regions in the context of the trimer upon binding remains to be studied.</p></sec><sec id="s2-3"><title>Germline VRC01-class Fabs recognize gp120 using signature VRC01-class contacts</title><p>The new germline Fab/gp120 structures, NIH45-46<sub>GL</sub>/426c.TM1△V1-3 and 3BNC60<sub>GL</sub>/426c.TM4△V1-3, showed interface interactions in which the germline Fab contacts with the CD4-binding loop and loops D and V5 of the gp120 outer domain were similar to those observed for mature VRC01-class Fab/gp120 complexes (<xref ref-type="bibr" rid="bib52">Zhou et al., 2010</xref>; <xref ref-type="bibr" rid="bib54">2015</xref>; <xref ref-type="bibr" rid="bib8">Diskin et al., 2011</xref>). This confirms the assumption of similar recognition modes derived from germline Fab-antigen complex structures that either did not contain a full gp120 core (VRC01<sub>GL</sub>/eOD-GT6) (<xref ref-type="bibr" rid="bib20">Jardine et al., 2013</xref>) or included a mature Ab LC (NIH45-46<sub>CHIM</sub>/93TH057) (<xref ref-type="bibr" rid="bib40">Scharf et al., 2013</xref>). In particular, both NIH45-46<sub>GL</sub> and 3BNC60<sub>GL</sub> interacted with the CD4-binding loop on gp120 using conserved interactions that mimic CD4 binding, first described for the complex of VRC01<sub>MAT</sub> with 93TH057 gp120 (<xref ref-type="bibr" rid="bib52">Zhou et al., 2010</xref>), in which VRC01-class bNAbs mimic CD4 using backbone atoms in the V<sub>H</sub> domain C” strand to engage with the CD4-binding loop on gp120 (<xref ref-type="bibr" rid="bib50">Wu et al., 2010</xref>; <xref ref-type="bibr" rid="bib52">Zhou et al., 2010</xref>; <xref ref-type="bibr" rid="bib54">2015</xref>; <xref ref-type="bibr" rid="bib8">Diskin et al., 2011</xref>). As found in NIH45-46<sub>MAT</sub> and 3BNC117<sub>MAT</sub> complexes with 93TH057 gp120s, Gly54<sub>HC</sub> in NIH45-46<sub>GL</sub> and 3BNC60<sub>GL</sub> makes a main chain hydrogen bond with Asp368<sub>gp120</sub> (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref>). The 3BNC60<sub>GL</sub> complex with 426c.TM4△V1-3 gp120 includes an additional main chain hydrogen bond between Gly57<sub>HC</sub> and Gly365<sub>gp120</sub> that is not made in the 3BNC117<sub>MAT</sub>/gp120 complex. Similarly, NIH45-46<sub>GL</sub> Thr58<sub>HC</sub> makes an additional side chain hydrogen bond with Gly365<sub>gp120</sub>. NIH45-46<sub>MAT</sub> further engages the CD4 binding loop of gp120 using water-mediated hydrogen bonds between Val57<sub>HC</sub> and Gly366<sub>gp120</sub>/Asp368<sub>gp120</sub> (<xref ref-type="bibr" rid="bib8">Diskin et al., 2011</xref>). While the resolution of the germline Fab complex structures did not permit placement of water molecules, residues in the C′′ strand of both NIH45-46<sub>GL</sub> and 3BNC60<sub>GL</sub> are positioned to engage in water-mediated hydrogen bonds with additional CD4-binding loop residues in gp120. Thus, our analyses showed that NIH45-46<sub>GL</sub> and 3BNC60<sub>GL</sub>, like their mature counterparts, use the C” strand in V<sub>H</sub> to mimic Leu44<sub>CD4</sub> and Lys46<sub>CD4</sub> interactions with the gp120 CD4 binding loop.<fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.13783.007</object-id><label>Figure 4.</label><caption><title>Comparison of Signature VRC01-class and CD4-mimickry Contacts in Germline Ab-gp120 Immunogen Complexes.</title><p>Top panels show (<bold>A</bold>) CD4 binding loop, (<bold>C</bold>) HC, (<bold>E</bold>) LC contacts in superimposed NIH45-46<sub>GL</sub>/426c.TM1△V1-3 and NIH45-46<sub>MAT</sub>/93TH057 (PDB 3U7Y) complexes. Bottom panels show (<bold>B</bold>) CD4-binding loop, (<bold>D</bold>) HC, (<bold>F</bold>) LC contacts in superimposed 3BNC60<sub>GL</sub>/426c.TM4△V1-3 and 3BNC117<sub>MAT</sub>/93TH057 (PDB 4JPV) complexes. Protein backbones are shown as wire diagrams, interacting residues are shown as stick representations (red, oxygen; blue, nitrogen). Yellow dashed lines indicate putative hydrogen bonds (distance &lt; 3.5 Å, A-H–D angle &gt; 90°). Ab coloring: blue, NIH45-46<sub>GL</sub> HC; light blue, NIH45-46<sub>GL</sub> LC; orange, NIH45-46<sub>MAT</sub> HC; yellow, NIH45-46<sub>MAT</sub> LC; green, 3BNC60<sub>GL</sub> HC; light green, 3BNC60<sub>GL</sub> LC; purple, 3BNC60<sub>MAT</sub> HC; light pink 3BNC60<sub>MAT</sub> LC. gp120 coloring: blue, CD4-binding loop; green, loop D; teal, loop V5. (E, F) Interacting residues of the C” strand of Fab HCs and the CD4-binding loop of gp120 (grey) are shown as sticks. The Fab residue numbers are indicated since the amino acid sequence differs at some positions between germline and mature Abs.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.13783.007">http://dx.doi.org/10.7554/eLife.13783.007</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-13783-fig4-v1"/></fig></p><p>We next examined the interactions of the VRC01-class signature residues (<xref ref-type="bibr" rid="bib48">Diskin et al., 2012</xref>). As found for mature VRC01-like Fab/gp120 complexes (e.g., PDB codes 3U7Y and 4JPV) and the half-germline NIH45-46<sub>CHIM</sub>/93TH057 gp120 complex (<xref ref-type="bibr" rid="bib40">Scharf et al., 2013</xref>), the VH1-2*02 germline-encoded heavy chain signature residues (Trp50<sub>HC</sub>, Asn58<sub>HC</sub>, Arg71<sub>HC</sub>) engaged in the predicted interactions with 426c.TM1△V1-3 and 426c.TM4△V1-3 in their complexes with NIH45-46<sub>GL</sub> and 3BNC60<sub>GL</sub>: i.e., Trp50<sub>HC</sub> and Asn58<sub>HC</sub> made hydrogen bonds with Asn280<sub>gp120</sub> and Arg456<sub>gp120</sub>, respectively, and Arg71<sub>HC</sub> formed a salt bridge with Asp368<sub>gp120</sub> to mimic the Arg59<sub>CD4</sub>–Asp368<sub>gp120</sub> interaction (<xref ref-type="bibr" rid="bib26">Kwong et al., 1998</xref>) (<xref ref-type="fig" rid="fig4">Figure 4C,D</xref>). The final signature interaction within the heavy chain, CDRH3 residue Trp100B<sub>HC</sub>, also made the predicted hydrogen bonding interaction with Asn279<sub>gp120</sub>. In summary, NIH45-46<sub>GL</sub> and 3BNC60<sub>GL</sub> make all predicted HC VRC01-class signature contacts with the CD4-binding loop, the V5 loop, and loop D to bind to gp120.</p><p>Potent VRC01-class bNAbs pair with LCs that acquire signature residues, Trp67<sub>LC</sub> and Glu96<sub>LC</sub>, during somatic hypermutation and/or V-J joining, and are associated with short loops for two of the CDRs: CDRL1 (resulting from a two- to four-residue deletion relative to the germline LC) and a five-residue CDRL3 (<xref ref-type="bibr" rid="bib48">Diskin et al., 2012</xref>). Comparison of the NIH45-46<sub>GL</sub>/426c.TM1△V1-3 and 3BNC60<sub>GL</sub>/426c.TM4△V1-3 structures with their mature counterparts (NIH45-46<sub>MAT</sub>/93TH057 and 3BNC117<sub>MAT</sub>/93TH057; PDB codes 3U7Y and 4JPV) revealed no major structural differences between the LC contacts with gp120 cores (<xref ref-type="fig" rid="fig4">Figure 4E,F</xref>). The greater number of residues in the CDRL1s in the germline Fab-containing complexes (two and four additional residues in NIH45-46<sub>GL</sub> and 3BNC60<sub>GL</sub>, respectively) result in wider, rather than longer, loops than their mature counterparts (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). The wider CDRL1s in the germline Fabs are not extended towards gp120, thereby preventing clashes with the 426c.TM1△V1-3 and 426c.TM4△V1-3 gp120s (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). However, CDRL1 is near the position of the Asn276<sub>gp120</sub><italic>N</italic>-linked glycan (removed by mutagenesis in gp120-based immunogen candidates including the 426c.TM1△V1-3 and 426c.TM4△V1-3 gp120s and the eOD-GT gp120 outer domains) (<xref ref-type="bibr" rid="bib31">McGuire et al., 2013</xref>; <xref ref-type="bibr" rid="bib32">2014</xref>; <xref ref-type="bibr" rid="bib33">2016</xref>; <xref ref-type="bibr" rid="bib20">Jardine et al., 2013</xref>; <xref ref-type="bibr" rid="bib21">2015</xref>). To address whether this glycan would clash with the larger CDRL1 loops of germline VRC01-class Abs, we superimposed the NIH45-46<sub>GL</sub>/426c.TM1△V1-3 and 3BNC60<sub>GL</sub>/426c.TM4△V1-3 complex structures with the structure of a mature Ab/gp120 complex that includes a partially ordered Asn276<sub>gp120</sub> glycan (the structure of 45-46m2 complexed with 93TH057 gp120 core; PDB code 4JKP) (<xref ref-type="bibr" rid="bib9">Diskin et al., 2013</xref>). The superimposed germline Fabs showed no clashes between CDRL1 and ordered Asn276<sub>gp120</sub> glycan residues (<xref ref-type="fig" rid="fig5">Figure 5B–D</xref>). However, given the flexibility of <italic>N</italic>-linked glycans, some conformations of the Asn276<sub>gp120</sub>-linked glycan could interfere with binding germline CD4bs Abs. VRC01-class Abs VRC-CH31 and 12A21 do not have deletions in CDRL1, but accommodate the Asn276<sub>gp120</sub>-linked glycan due to a pair of glycines that increase the conformational flexibility of CDRL1 (<xref ref-type="bibr" rid="bib53">Zhou et al., 2013</xref>). The CDRL1 of 3BNC60<sub>GL</sub> is of the same length as the VRC-CH31 and 12A21 CDRL1s and lacks glycines, yet has the conformational flexibility to avoid clashes with loop D<sub>gp120</sub> and the Asn276<sub>gp120</sub> glycan (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Therefore, CDRL1 deletions or enhanced loop flexibility due to somatically substituted glycine residues is not required for binding to gp120 although these adaptations likely lead to improved affinity in mature bNAbs adapted to bind to HIV-1 Envs that are not optimized to accommodate germline Ab binding.<fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.13783.008</object-id><label>Figure 5.</label><caption><title>Accommodation of Asn276<sub>gp120</sub> Glycan by Germline Ab Light Chains.</title><p>Superposition of gp120 (grey) complexes with germline and mature Abs. (<bold>A</bold>) CDRL1 from 45-46m2<sub>MAT</sub> (yellow), NIH45-46<sub>GL</sub> (blue) and 3BNC60<sub>GL</sub> (green) is positioned near the Asn276<sub>gp120</sub> glycan. Two- and four-residue insertions in NIH45-46<sub>GL</sub> and 3BNC60<sub>GL</sub>, respectively, result in a widening of the tip of CDRL1 rather than a more extended loop, which would clash with gp120 protein residues and/or the Asn276<sub>gp120</sub> glycan. gp120 (grey) complexes with (<bold>B</bold>) 3BNC117<sub>MAT</sub> (pink) and 45-46m2<sub>MAT</sub> (yellow) (<bold>C</bold>) NIH45-46<sub>GL</sub> (blue) and 45-46m2<sub>MAT</sub> (yellow), (<bold>D</bold>) 3BNC60<sub>GL</sub> (green) and 45–46 m2<sub>MAT</sub> (yellow). Protein backbones are shown as wire diagrams and the Asn276<sub>gp120</sub> glycan from the 45-46m2<sub>MAT</sub>/93TH057 gp120 complex (PDB code 4JKP) is shown as sticks (yellow, carbon; red, oxygen; blue, nitrogen). The positions of CDRL1 and FWR3<sub>LC</sub> are indicated. (<bold>E</bold>) CDRL1 from VRC-CH31<sub>MAT</sub> (magenta), NIH45-46<sub>GL</sub> (blue) and 3BNC60<sub>GL</sub> (green) is positioned near the Asn276<sub>gp120</sub> glycan. The CDRL1 loop of VRC-CH31<sub>MAT</sub> is of the same length as that of 3BNC60<sub>GL</sub>, and uses increased backbone conformational flexibility due to somatically mutated glycine residues to avoid clashes with gp120 protein residues and/or the Asn276<sub>gp120</sub> glycan.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.13783.008">http://dx.doi.org/10.7554/eLife.13783.008</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-13783-fig5-v1"/></fig></p></sec><sec id="s2-4"><title>Comparison of interface buried surface areas for germline and mature Fab complexes with gp120 immunogens</title><p>We previously noted that the buried surface area on both the Ab and the gp120 was larger in mature Fab/gp120 complexes than in the NIH45-46<sub>CHIM</sub>/93TH057 gp120 complex (<xref ref-type="bibr" rid="bib40">Scharf et al., 2013</xref>). Here, we extended this analysis to include comparisons with the HC/LC germline Fab complexes with 426c.TM1△V1-3 and 426c.TM4△V1-3 (<xref ref-type="fig" rid="fig6">Figure 6A,B</xref>, <xref ref-type="supplementary-material" rid="SD2-data">Supplementary file 1</xref>). The surface area buried on gp120 by both germline Fabs was only slightly smaller than that buried by the corresponding mature Abs (1,039 Å<sup>2</sup> vs. 1,190 Å<sup>2</sup> for NIH45-46<sub>GL</sub> vs. NIH45-46<sub>MAT</sub> and 939 Å<sup>2</sup> vs. 1,033 Å<sup>2</sup> for 3BNC60<sub>GL</sub> vs. 3BNC117<sub>MAT</sub>), with gains in buried surface area in loop D, inner domain and bridging sheet residues of gp120 (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). The surface area buried on the Fab HCs by gp120 was smaller than that buried by the corresponding mature Abs with no change in the area buried on the LCs (784 Å<sup>2</sup> vs. 1,130 Å<sup>2</sup> for NIH45-46<sub>GL</sub> HC vs. NIH45-46<sub>MAT</sub> HC and 731 Å<sup>2</sup> vs. 802 Å<sup>2</sup> for 3BNC60<sub>GL</sub> vs. 3BNC117<sub>MAT</sub>). The difference was most pronounced for the NIH45-46<sub>GL</sub>/NIH45-46<sub>MAT</sub> comparison, in which the mature Fab gained contacts in CDRH3.<fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.13783.009</object-id><label>Figure 6.</label><caption><title>Comparison of the Binding Interfaces in gp120 Complexes with Germline and Mature Abs.</title><p>(<bold>A</bold>) gp120 residues contacted by Fabs and (<bold>B</bold>) Fab residues contacted by gp120s are shown as surfaces over ribbon diagrams. gp120 domains are colored as in <xref ref-type="fig" rid="fig3">Figure 3</xref>. Ab coloring: blue, NIH45-46<sub>GL</sub> HC; light blue, NIH45-46<sub>GL</sub> LC; purple, NIH45-46<sub>CHIM</sub> HC; light purple, NIH45-46<sub>CHIM</sub> LC; orange, NIH45-46<sub>MAT</sub> HC; yellow, NIH45-46<sub>MAT</sub> LC; green, 3BNC60<sub>GL</sub> HC; light green, 3BNC60<sub>GL</sub> LC; pink, 3BNC60<sub>MAT</sub> HC; light pink, 3BNC60<sub>MAT</sub> LC. (<bold>C</bold>) Quantitation of buried surface areas (Å<sup>2</sup>) depicted in (<bold>A</bold>) and (<bold>B</bold>). The columns labeled total are the sums of areas for outer domain, bridging sheet and inner domain for gp120, and of heavy chain and light chain for Abs. Surface areas buried due to complex formation were calculated using a 1.4 Å probe.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.13783.009">http://dx.doi.org/10.7554/eLife.13783.009</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-13783-fig6-v1"/></fig></p></sec><sec id="s2-5"><title>Differences in approach angle for Abs complexed with 426c-based gp120 immunogens</title><p>Mature VRC01-class Abs show similar angles of approach for binding to gp120 ([Zhou et al., undefined] and references therein). However, comparison of the orientations of the germline Fab interactions with gp120 in the NIH45-46<sub>GL</sub>/426c.TM1△V1-3 and 3BNC60<sub>GL</sub>/426c.TM4△V1-3 structures revealed differences compared with their mature Fab counterparts (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). To systematically analyze these differences, we calculated the rotation and translation for the V<sub>H</sub> domains of mature, chimeric, and germline Fabs bound to gp120s when compared with a reference Fab/gp120 structure, the VRC01<sub>MAT</sub>/93TH057 complex (<xref ref-type="bibr" rid="bib52">Zhou et al., 2010</xref>) (PDB code 3NGB) (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). We found that the mature Fab/gp120 complex structures clustered in the recognition mode for VRC01-class Ab recognition of gp120 (Zhou et al., undefined). The germline Fab complexes with the 426c gp120 immunogens exhibited larger rotations and translations relative to the VRC01 reference structure, with the VRC01<sub>GL</sub>/eOD-GT6 complex showing an intermediate orientation. To verify that the orientations observed for the germline Fabs bound to the 426c gp120s are relevant for binding to Env trimer, we aligned the 3BNC60<sub>GL</sub>/426c.TM4△V1-3 structure onto the gp120 region of a native-like Env trimer structure (BG505 SOSIP.664; PDB code 5CEZ) (<xref ref-type="bibr" rid="bib16">Garces et al., 2015</xref>), comparing this orientation with the alignment of a VRC01<sub>MAT</sub>/gp120 complex (PDB code 3NGB) (<xref ref-type="bibr" rid="bib52">Zhou et al., 2010</xref>) onto the same Env trimer structure (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). This alignment suggests that the different orientation of the 3BNC60<sub>GL</sub> V<sub>H</sub> domain with respect to gp120 moves it away from the adjacent gp120 subunit, suggesting this orientation would be sterically compatible when binding to Env trimer.<fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.13783.010</object-id><label>Figure 7.</label><caption><title>Comparisons of Binding Mode in Germline Ab-gp120 Immunogen Complexes.</title><p>(<bold>A</bold>) Superpositions of Fab-gp120 complexes depicted as wire diagrams. The following Fab/gp120 complexes were compared by alignment of their gp120s: 3BNC117<sub>MAT</sub>/93TH057 (PDB code 4JPV), 3BNC117<sub>MAT</sub>/C1086 (PDB code 4LSV), 3BNC117<sub>MAT</sub>/93TH057 (PDB code 4JPV), 3BNC60<sub>GL</sub>/426c.TM4△V1-3, NIH45-46<sub>MAT</sub>/93TH057 (PDB code 3U7Y), VRC01<sub>MAT</sub>/KER.2018.11 (PDB code 4LSS), NIH45-46<sub>GL</sub>/426c.TM1△V1-3. (<bold>B</bold>) Rotation angle and translation distance of V<sub>H</sub> domains of mature, chimeric and germline Fabs in complex with gp120s relative to VRC01<sub>MAT</sub> in complex with 93TH057 gp120 (PDB code 3NGB). Data points for complexes of mature Fabs bound to non-immunogen gp120s are shown as blue diamonds, complexes of germline Fabs bound to immunogen candidates are shown as red squares (TM1 = 426c.TM1△V1-3, TM4 = 426c.TM4△V1-3, eOD = eOD-GT6), the complex between the half mature, half germline NIH45-46<sub>CHIM</sub> and to a non-immunogen gp120 is shown as a purple diamond, and 3BNC55<sub>MAT</sub> bound to 426c.TM4△V1-3 is shown as a green square. When two complexes were found in the crystallographic asymmetric unit, rotation and translation parameters are shown for both complexes (denoted as #1 and #2). Standard deviations for the translation distance and rotation angle for mature VRC01-class bNAb–gp120 complexes shown as vertical and horizontal lines, respectively. (<bold>C</bold>) Alignment of the 3BNC60<sub>GL</sub>/426c.TM4△V1-3 (V<sub>H</sub>V<sub>L</sub> shown in red) and VRC01<sub>MAT</sub> Fab/gp120 (PDB code 3NGB) (V<sub>H</sub>V<sub>L</sub> shown in blue) structures onto the gp120 region of a native-like Env trimer structure (BG505 SOSIP.664; PDB code 5CEZ) (gray). Modeled structures are shown looking down the trimer three-fold axis (left panel) and from the side (right panel).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.13783.010">http://dx.doi.org/10.7554/eLife.13783.010</ext-link></p><p><supplementary-material id="SD1-data"><object-id pub-id-type="doi">10.7554/eLife.13783.011</object-id><label>Figure 7—source data 1.</label><caption><title>Rotation angle and translation distance data of V<sub>H</sub> domains of mature, chimeric and germline Fabs in complex with gp120s relative to VRC01<sub>MAT</sub> in complex with 93TH057 gp120.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.13783.011">http://dx.doi.org/10.7554/eLife.13783.011</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-13783-fig7-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-13783-fig7-v1"/></fig></p><p>The orientation differences for the NIH45-46<sub>GL</sub>/426c.TM1△V1-3 and 3BNC60<sub>GL</sub>/426c.TM4△V1-3 structures could result from structural characteristics of germline Fabs, immunogen characteristics allowing for germline Fab recognition, or a combination of these factors. Arguing in favor of the idea that the 426c immunogens could select for an altered binding mode, we note that a mature Ab (3BNC55<sub>MAT</sub>) complex with 426c.TM4△V1-3 exhibited rotation and translation values closer to those of the germline Fab/426c immunogen complexes than those of mature Ab-gp120 complexes. In addition, the VRC01<sub>GL</sub> complex with another germline-binding immunogen, eOD-GT6, exhibited a binding mode that differed from the VRC01 reference complex more than most of the mature Fab/gp120 complexes. We also note that the half germline NIH45-46<sub>CHIM</sub> Fab clustered with the mature Fab/gp120 complexes when bound to the 93TH057 gp120 (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). This is consistent with the idea that designed immunogens capable of binding germline VRC01-class bNAbs select for a slightly different antibody-binding mode than that adopted by mature VRC01-class Fabs bound to gp120s not capable of supporting germline antibody binding.</p></sec><sec id="s2-6"><title>Interactions with complex-type <italic>N</italic>-glycans may be facilitated by electrostatic changes in Fab combining sites during maturation</title><p>To address potential global changes in VRC01-class bNAbs during maturation from germline to mature forms, we calculated electrostatic potentials of the binding surfaces of germline and mature Fabs. Comparisons of electrostatic surface potentials revealed a striking shift to more positively-charged antigen combining sites due to maturation (<xref ref-type="fig" rid="fig8">Figure 8</xref>). The more negatively-charged (3BNC60<sub>GL</sub>) or neutral (NIH45-46<sub>GL</sub>, VRC01<sub>GL</sub>) properties of the antigen-binding sites of the germline Fabs may interfere with interactions with complex-type <italic>N</italic>-glycans on gp120 containing negatively-charged sialic acids; in particular, the Asn276<sub>gp120</sub> carbohydrate, typically a complex-type <italic>N</italic>-glycan (<xref ref-type="bibr" rid="bib4">Binley et al., 2010</xref>; <xref ref-type="bibr" rid="bib18">Go et al., 2011</xref>), would likely make unfavorable interactions with the neutral or negatively charged surfaces of 3BNC60<sub>GL</sub>, NIH45-46<sub>GL</sub>, or VRC01<sub>GL</sub> Fabs. Such interactions were prevented in the 426c gp120- and eOD-based immunogens by mutation of the Asn276<sub>gp120</sub><italic>N</italic>-linked glycosylation sequon (<xref ref-type="bibr" rid="bib31">McGuire et al., 2013</xref>; <xref ref-type="bibr" rid="bib32">2014</xref>; <xref ref-type="bibr" rid="bib20">Jardine et al., 2013</xref>; <xref ref-type="bibr" rid="bib21">2015</xref>). Similarly, potentially unfavorable electrostatic interactions between the germline Fabs and the Asn463<sub>gp120</sub><italic>N</italic>-linked glycan, also usually a complex-type <italic>N</italic>-glycan (<xref ref-type="bibr" rid="bib4">Binley et al., 2010</xref>; <xref ref-type="bibr" rid="bib18">Go et al., 2011</xref>), were prevented by mutation of the Asn463<sub>gp120</sub> glycosylation sequon in the 426c gp120- and eOD-based immunogens (<xref ref-type="bibr" rid="bib31">McGuire et al., 2013</xref>; <xref ref-type="bibr" rid="bib32">2014</xref>; <xref ref-type="bibr" rid="bib33">2016</xref>; <xref ref-type="bibr" rid="bib20">Jardine et al., 2013</xref>; <xref ref-type="bibr" rid="bib21">2015</xref>).<fig-group><fig id="fig8" position="float"><object-id pub-id-type="doi">10.7554/eLife.13783.012</object-id><label>Figure 8.</label><caption><title>Comparison of Electrostatic Surface Characteristics of Fab-gp120 Complexes.</title><p>The binding surfaces of Fabs (left panels) and gp120s (right panels) are shown. Each binding partner is shown in an orientation looking into the binding interface; the corresponding complex would be obtained by rotating each binding partner by ~90˚ about the vertical axis. The top panel shows the locations of landmarks on surface representations of Fabs (dark grey, V<sub>H</sub>; light grey, V<sub>L</sub>) and gp120s (yellow, outer domain; grey, inner domain; orange, bridging sheet; blue, CD4-binding loop; green, loop D; teal, loop V5; ordered residues of the Asn276<sub>gp120</sub> glycan shown as yellow sticks (normally a complex-type <italic>N</italic>-glycan, but a high mannose <italic>N</italic>-glycan in crystal structures); approximate locations of Asn460<sub>gp120</sub> and Asn463<sub>gp120</sub> shown as light pink and magenta dots, respectively). The lower panels show electrostatic potentials on surface representations of Fabs (left panels) and gp120s (right panels) colored blue (positive electrostatic potential) to red (negative electrostatic potential). The binding interfaces are outlined with a dotted black line. The approximate footprints of the complex-type Asn276<sub>gp120</sub> glycan on Fab surfaces are indicated with a black triangle (the Asn463<sub>gp120</sub> glycan, also complex-type, is not resolved in any Env structures, thus its footprint on Fab surfaces cannot be shown).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.13783.012">http://dx.doi.org/10.7554/eLife.13783.012</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-13783-fig8-v1"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.13783.013</object-id><label>Figure 8—figure supplement 1.</label><caption><title>The combining sites of germline (left panels) and mature Fabs (right panels) are shown as surface representations and electrostatic potentials are indicated using blue for positive electrostatic potential and red for negative electrostatic potential.</title><p>Abs shown are CH58<sub>GL</sub> and CH58<sub>MAT</sub> (PDB codes 4RIR and 4HPO), 4E10<sub>GL</sub> and 4E10<sub>MAT</sub> (PDB codes 4ODX and 2FX7), 10-1074<sub>GL</sub> and 10-1074<sub>MAT</sub> (PDB codes 4FQQ and 4FQ2) (shown in two orientations to better illustrate electrostatic changes), and CH103<sub>GL</sub> and CH103<sub>MAT</sub> (PDB codes 4QHK and 4JAM). The antibody paratopes are outlined with a dotted black line. The approximate footprint of Asn137<sub>gp120</sub>, Asn156<sub>gp120</sub> and Asn332<sub>gp120</sub> glycans on 10-1074<sub>GL</sub> and 10-1074<sub>MAT</sub> Fab surfaces are indicated with black triangles.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.13783.013">http://dx.doi.org/10.7554/eLife.13783.013</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-13783-fig8-figsupp1-v1"/></fig></fig-group></p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The process by which B cells produce high-affinity Abs starts with antigen binding to an unmutated, germline B cell receptor produced by random joining of V, D, and J or V and J gene segments. Affinity maturation is the process by which Abs with higher antigen-binding affinity are created through somatic hypermutation of the germline B cell receptor (<xref ref-type="bibr" rid="bib46">Victora and Nussenzweig, 2012</xref>). Many anti-HIV-1 bNAbs, including VRC01-class CD4bs bNAbs, are heavily somatically mutated, likely through successive rounds of hypermutation and selection of B cells in response to rapid mutation of HIV-1 Env (<xref ref-type="bibr" rid="bib49">West et al., 2014</xref>; <xref ref-type="bibr" rid="bib23">Klein et al., 2013</xref>). Mature VRC01-class bNAbs achieve nucleotide somatic mutation frequencies of 32% and 20% in HC and LC variable region genes, respectively, whereas the mutation frequencies of more typical affinity-matured human Abs rarely exceeds 10% (<xref ref-type="bibr" rid="bib27">Kwong and Mascola, 2012</xref>). Although heavily somatically mutated, VRC01-class bNAbs are promising targets for vaccine design because they have evolved in multiple donors from a common human germline V<sub>H</sub> gene segment, VH1-2*02, to recognize HIV-1 Env using conserved interactions (<xref ref-type="bibr" rid="bib41">Scheid et al., 2011</xref>; <xref ref-type="bibr" rid="bib50">Wu et al., 2010</xref>; Zhou et al., undefined; <xref ref-type="bibr" rid="bib53">Zhou et al., 2013</xref>; <xref ref-type="bibr" rid="bib8">Diskin et al., 2011</xref>; <xref ref-type="bibr" rid="bib52">Zhou et al., 2010</xref>).</p><p>The first step in targeted attempts to raise VRC01-class bNAbs by immunization requires identification of an immunogen that binds to the germline configuration of the B-cell receptor, but germline-reverted versions of VRC01-like bNAbs generally do not bind HIV-1 Env (<xref ref-type="bibr" rid="bib41">Scheid et al., 2011</xref>; <xref ref-type="bibr" rid="bib52">Zhou et al., 2010</xref>; <xref ref-type="bibr" rid="bib48">Diskin et al., 2012</xref>; <xref ref-type="bibr" rid="bib40">Scharf et al., 2013</xref>; <xref ref-type="bibr" rid="bib19">Hoot et al., 2013</xref>; <xref ref-type="bibr" rid="bib48">Ota et al., 2012</xref>; <xref ref-type="bibr" rid="bib31">McGuire et al., 2013</xref>; <xref ref-type="bibr" rid="bib20">Jardine et al., 2013</xref>). Although antigens designed to bind to predicted unmutated germline precursors of VRC01-class bNAbs have been constructed and evaluated (<xref ref-type="bibr" rid="bib31">McGuire et al., 2013</xref>; <xref ref-type="bibr" rid="bib32">2014</xref>; <xref ref-type="bibr" rid="bib33">2016</xref>; <xref ref-type="bibr" rid="bib20">Jardine et al., 2013</xref>; <xref ref-type="bibr" rid="bib21">2015</xref>; <xref ref-type="bibr" rid="bib11">Dosenovic et al., 2015</xref>), structural comparisons of germline and mature versions of VRC01-class bNAbs bound to gp120-based immunogens were not available. Here, we report the results of structural studies of immunogens that bind to the inferred germline precursors of VRC01-class bNAbs, discovering both general principles and details of interactions that can guide structure-based immunogen design.</p><p>A surprising finding revealed by our structural comparisons of germline and mature VRC01-class Fabs was an increase in electropositive surface potential in the antigen-combining site for the mature Fab compared with the germline-inferred Fab, which we observed in the three VRC01-class Abs (NIH45-46, 3BNC60, and VRC01) for which germline and mature Fab structures were available for calculating electrostatic potentials. This marked shift to a more electropositive antigen combining site may also occur in other VRC01-class bNAbs, particularly those whose LCs are derived from the LC germline <italic>K</italic>V1-33 gene segment. Mature VRC01-class bNAbs appear on average to have a higher net nominal charge of their V<sub>H</sub>V<sub>L</sub> domains (+4.9) than the average human Ab (+3.1; as calculated from sequenced human B-cell repertoires) (<xref ref-type="table" rid="tbl2">Table 2</xref>) (<xref ref-type="bibr" rid="bib48">Rubelt et al., 2012</xref>), and the VH1-2*02 gene segment yields a sequence with a nominal net charge of +5, higher than the average human V<sub>H</sub> gene segment (+2 to +3). However, the <italic>K</italic>V1-33 LC germline gene segment, used by some VRC01-class Abs, yields a protein sequence with a nominal net charge of -4, in contrast to the <italic>K</italic>V3-20 gene segment (utilized by other VRC01-class Abs) with a net charge of zero. Perhaps to compensate for these negative charges, after maturation of the <italic>K</italic>V1-33–derived VRC01-class bNAbs 3BNC117, VRC-CH31, and 12A12, the portions of the V<sub>L</sub> domain encoded by the <italic>K</italic>V1-33 gene segment have net nominal charge changes of +5, +3, and +6, respectively.<table-wrap id="tbl2" position="float"><object-id pub-id-type="doi">10.7554/eLife.13783.014</object-id><label>Table 2.</label><caption><p>Nominal net charges of VRC01-class bNAbs and of the human Ab repertoire. Nominal net charge is the total charge of the sequence calculated with Asp/Glu as -1 and Arg/Lys as +1. The human Ab repertoire average is calculated from 601,889 HC and 206,953 LC sequences reported in (<xref ref-type="bibr" rid="bib39">Rubelt et al., 2012</xref>). Light chain Vgene assignments are from (<xref ref-type="bibr" rid="bib54">Zhou et al., 2015</xref>). Standard deviations are indicated, except for human Ab repertoire V<sub>H</sub> + V<sub>L</sub>, which cannot be calculated with unpaired chains. *Two-tailed T test comparing the net charges of VRC01-class VHs with human repertoire V<sub>H</sub>s gives a p-value of 0.01.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.13783.014">http://dx.doi.org/10.7554/eLife.13783.014</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="3">Nominal Net Charge</th><th/></tr></thead><tbody><tr><td>Ab</td><td>V<sub>H</sub> + V<sub>L</sub></td><td>V<sub>H</sub></td><td>V<sub>L</sub></td><td>LC V-gene</td></tr><tr><td>VRC01</td><td>5</td><td>4</td><td>1</td><td><italic>K</italic>3-20</td></tr><tr><td>NIH45-46</td><td>9</td><td>8</td><td>1</td><td><italic>K</italic>3-20</td></tr><tr><td>3BNC117</td><td>5</td><td>2</td><td>3</td><td><italic>K</italic>1-33</td></tr><tr><td>12A12</td><td>5</td><td>1</td><td>4</td><td><italic>K</italic>1-33</td></tr><tr><td>VRC-PG04</td><td>7</td><td>3</td><td>4</td><td><italic>K</italic>3-20</td></tr><tr><td>VRC-CH31</td><td>2</td><td>2</td><td>0</td><td><italic>K</italic>1-33</td></tr><tr><td>VRC-PG20</td><td>4</td><td>5</td><td>-1</td><td><italic>L</italic>2-14</td></tr><tr><td>VRC23</td><td>5</td><td>4</td><td>1</td><td><italic>K</italic>3-15</td></tr><tr><td>VRC18</td><td>3</td><td>2</td><td>1</td><td><italic>K</italic>3-20</td></tr><tr><td>VRC27</td><td>4</td><td>6</td><td>-2</td><td><italic>K</italic>1-33</td></tr><tr><td>Average of VRC01-class bNAbs</td><td>4.9 ± 1.9</td><td>3.7* ± 2.1</td><td>1.2 ± 1.9</td><td/></tr><tr><td>Human Ab repertoire average</td><td>3.1</td><td>1.5 ± 2.4</td><td>1.6 ± 2.1</td><td/></tr></tbody></table></table-wrap></p><p>The trend towards increased electropositivity with Ab maturation does not apply to all HIV-1 Env-specific Abs: maturation of CH58, a non-neutralizing Ab against the gp120 V2 loop that was raised by vaccination in the RV144 trial (<xref ref-type="bibr" rid="bib29">Liao et al., 2013</xref>), did not involve a shift to increased electropositive character (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>), consistent with its epitope being centered on a positive residue, Lys169<sub>gp120</sub>, within the gp120 V2 loop (<xref ref-type="bibr" rid="bib35">Nicely et al., 2015</xref>). However, the developmental pathway of potent V1V2-directed bNAbs involves increased positivity of the CDRH3 loop, which starts as highly electronegative in part due to sulfated tyrosines, but accumulates positive charges during maturation that partially compensate for the negatively-charged sulfates (<xref ref-type="bibr" rid="bib10">Doria-Rose et al., 2014</xref>). A trend towards electropositive combining sites in mature HIV-1 bNAbs could rationalize their tendencies towards polyreactivity (binding more than one antigen), which has been observed at higher frequencies for broadly neutralizing, as compared with non-neutralizing, Abs against HIV-1 (<xref ref-type="bibr" rid="bib30">Liu et al., 2015</xref>). For example, increased non-specific binding to cardiolipin and nucleic acids, negatively-charged antigens commonly used in polyreactivity assays, correlates with polyreactive properties of Abs (<xref ref-type="bibr" rid="bib34">Mouquet et al., 2010</xref>).</p><p>We suggest that evolution of increased electropositivity during maturation of VRC01-class bNAbs (and perhaps other HIV-1 bNAbs; <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>) facilitates interactions with heavily glycosylated HIV-1 Env spikes that include complex <italic>N</italic>-linked glycans containing negatively charged sialic acids. Indeed, somatic hypermutation to increase electropositivity of an Ab combining site may be a strategy utilized by Abs against other viruses containing heavily glycosylated Env proteins, such as influenza and Ebola. In the case of VRC01-class bNAbs, this strategy may be part of a multi-pronged approach of the humoral immune response against the CD4 binding site of HIV-1 for accommodating and/or for avoiding the <italic>N</italic>-linked Env glycan attached to Asn276<sub>gp120</sub>, a site that can include complex-type <italic>N</italic>-glycans (<xref ref-type="bibr" rid="bib3">Behrens et al., 2016</xref>), with other strategies including deletions to shorten CDRL1 and increasing CDRL1 flexibility by somatic mutations to glycine (<xref ref-type="bibr" rid="bib53">Zhou et al., 2013</xref>). In addition to these steric considerations for potentially unfavorable interactions between CDRL1 and the Asn276<sub>gp120</sub>-linked glycan, the neutral or negatively charged character of the germline Fab combining sites provides a structural justification for the necessity to eliminate the Asn276<sub>gp120</sub>- and Asn463<sub>gp120</sub>-linked <italic>N</italic>-glycans from eOD- and gp120-based immunogen candidates to achieve binding to inferred germline B-cell receptors (<xref ref-type="bibr" rid="bib31">McGuire et al., 2013</xref>; <xref ref-type="bibr" rid="bib20">Jardine et al., 2013</xref>; <xref ref-type="bibr" rid="bib21">2015</xref>; <xref ref-type="bibr" rid="bib32">McGuire et al., 2014</xref>; <xref ref-type="bibr" rid="bib33">2016</xref>). The structures presented here, taken together with immunogen requirements for achieving germline Ab binding and previous structural analyses of mature VRC01-class Abs (Zhou et al., undefined; <xref ref-type="bibr" rid="bib52">Zhou et al., 2010</xref>; <xref ref-type="bibr" rid="bib53">2013</xref>; <xref ref-type="bibr" rid="bib31">McGuire et al., 2013</xref>; <xref ref-type="bibr" rid="bib32">2014</xref>; <xref ref-type="bibr" rid="bib33">2016</xref>; <xref ref-type="bibr" rid="bib20">Jardine et al., 2013</xref>; <xref ref-type="bibr" rid="bib21">2015</xref>), suggest that the initiating antigen(s) in a natural pathway to induce VRC01-class Abs in HIV-1–infected individuals involve viral variants that lack the Asn276<sub>gp120</sub> (5% of HIV-1 strains in the Los Alamos Database) and the Asn463<sub>gp120</sub><italic>N</italic>-glycans (~80% of HIV-1 strains in the Los Alamos Database) (<ext-link ext-link-type="uri" xlink:href="http://www.hiv.lanl.gov/content/index">http://www.hiv.lanl.gov/content/index</ext-link>). Alternatively, a natural VRC01-class eliciting antigen could be the result of glycan heterogeneity within a single HIV-1 strain that produced variants containing high mannose, rather than complex-type, <italic>N</italic>-glycans at Asn276<sub>gp120</sub> and/or Asn463<sub>gp120</sub>, consistent with observations of glycan heterogeneity at individual <italic>N</italic>-linked glycosylation sites within single HIV-1 strains (<xref ref-type="bibr" rid="bib18">Go et al., 2011</xref>; <xref ref-type="bibr" rid="bib3">Behrens et al., 2016</xref>).</p><p>Although antibody-antigen recognition modes represent a continuum of binding mechanisms, germline precursors to affinity-matured Abs have been suggested to display structural flexibility to allow expanded antigen recognition through induced fit mechanisms, whereas affinity maturation through somatic hypermutation was assumed to convert recognition to a lock-and-key model (<xref ref-type="bibr" rid="bib15">Foote and Milstein, 1994</xref>; <xref ref-type="bibr" rid="bib47">Wedemayer et al., 1997</xref>; <xref ref-type="bibr" rid="bib44">Thorpe and Brooks, 2007</xref>). Induced fit modes of Ab-antigen recognition involve changes in the conformations of backbone and sidechain atoms of both the Ab and the antigen (<xref ref-type="bibr" rid="bib5">Blackler et al., 2011</xref>; <xref ref-type="bibr" rid="bib28">Li et al., 2007</xref>; <xref ref-type="bibr" rid="bib38">Rosen et al., 2005</xref>; <xref ref-type="bibr" rid="bib43">Sinha and Smith-Gill, 2005</xref>; <xref ref-type="bibr" rid="bib45">Verdaguer et al., 1996</xref>), with large changes in the Ab usually occurring in the CDR loops. By contrast, lock-and-key recognition involves a minimum of conformational changes between the bound and unbound states of the antigen and Ab. Here, we showed that for the VRC01 class of CD4bs bNAbs, the maturation pathway for antigen binding from germline Ab to affinity-matured Ab does not involve changes from induced fit to lock-and-key binding mechanisms. Instead, the 426c gp120 immunogens bind NIH45-46<sub>GL</sub> and 3BNC60<sub>GL</sub> without requiring notable conformational changes in either the Ab or the antigen; thus both are largely preformed for binding. The largely lock-and-key binding mechanism for germline VRC01-class recognition of antigen may be rationalized by the fact that germline VRC01-class CD4bs Abs face major steric constraints when binding to HIV-1 Env trimer due to the recessed location of the epitope and its shielding by glycans from the target and adjacent gp160 monomers (<xref ref-type="bibr" rid="bib49">West et al., 2014</xref>; <xref ref-type="bibr" rid="bib54">Zhou et al., 2015</xref>). VRC01-like CD4bs bNAbs bind Env at an acute angle using mostly CDRs and FWRs of V<sub>H</sub> in part because these steric constraints likely do not allow a Fab to bind perpendicular to the CD4bs on a closed Env trimer without clashes with the adjacent trimer subunit. These constraints may also not permit bNAbs or their germline precursors to undergo the major conformational changes characteristic of induced-fit binding and instead select for rare Ab sequences that are preformed to recognize their epitope in this highly sterically-constrained setting. The lock-and-key binding mechanism of VRC01-class recognition also may reflect that the binding interaction is dominated (relative to other Abs) by V<sub>H</sub> domain FWRs, and that these would be unlikely to undergo large induced-fit conformational changes.</p><p>Structural analyses of germline and mature versions of the non-neutralizing HIV-1 Ab CH58 showed a more typical path for Ab-antigen recognition; the germline precursor used a combination of induced fit and lock-and-key binding modes to recognize a V2 peptide antigen: its CDRL2 loop was preformed for binding but CDRL3 changed conformation upon antigen binding (<xref ref-type="bibr" rid="bib35">Nicely et al., 2015</xref>). The conformation of CDRL3 became fixed in mature CH58 through limited somatic mutation compared with VRC01-class Abs (11 total substitutions in CH58 V<sub>H</sub>V<sub>L</sub>) (<xref ref-type="bibr" rid="bib35">Nicely et al., 2015</xref>). Thus, the conversion from induced fit to lock-and-key binding may be applicable for HIV-1 Abs such as CH58 that include the relatively small numbers of somatic mutations typical for most Abs, but not for VRC01-class Abs, whose maturation process involves a much higher number (&gt;60) of mutations.</p><p>The finding of what can be described as lock-and-key recognition for germline Fabs binding to the 426c gp120 immunogens contrasts with recognition of unmodified gp120s used for structural studies of complexes with mature VRC01-class bNAbs that do not bind or bind only poorly to germline Abs. For example, when bound to the unmodified 93TH057 gp120, the CDRH3 of the germline HC in the NIH45-46<sub>CHIM</sub>-93TH057 complex structure was partially disordered, presumably to avoid clashes with a gp120 not optimized for binding to germline Abs (<xref ref-type="bibr" rid="bib40">Scharf et al., 2013</xref>). An example of structural rearrangements in a mature VRC01-class bNAb bound to an unmodified gp120 is illustrated by a study of the Ala61<sub>HC</sub>Pro substitution in the C” β-strand of the β-sheet framework in the V<sub>H</sub> domains of the 3BNC60/3BNC117 HIV-1 bNAbs. This substitution is required for maximal neutralization potency of the mature bNAbs, yet it disrupts the C” β-strand of the V<sub>H</sub> domain in the unbound Fab and decreases its thermal stability (<xref ref-type="bibr" rid="bib23">Klein et al., 2013</xref>), with the β-sheet framework being restored through a large conformational change when the mature Fab binds gp120 (<xref ref-type="bibr" rid="bib53">Zhou et al., 2013</xref>; <xref ref-type="bibr" rid="bib23">Klein et al., 2013</xref>). Taken together, the findings of what appears to be lock-and-key style germline Fab recognition with increased flexibility upon maturation for the highly somatically-mutated VRC01-class bNAbs contradict the assumption of induced fit for germline Ab recognition and lock-and-key fit for mature Ab binding (<xref ref-type="bibr" rid="bib15">Foote and Milstein, 1994</xref>; <xref ref-type="bibr" rid="bib47">Wedemayer et al., 1997</xref>; <xref ref-type="bibr" rid="bib44">Thorpe and Brooks, 2007</xref>). This assumption was also challenged by studies of the maturation of other HIV-1 Abs: for example, CH103, a non-VRC01-class CD4-binding site bNAb, exhibits changes in the relative orientation of its V<sub>H</sub> and V<sub>L</sub> domains during maturation (<xref ref-type="bibr" rid="bib13">Fera et al., 2014</xref>), and the HIV-1 gp41-directed bNAb 4E10 exhibits increased flexibility in its combining site during maturation (<xref ref-type="bibr" rid="bib14">Finton et al., 2014</xref>). Thus, the rare events that result in evolution of HIV-1 bNAbs can fall outside of typical Ab maturation pathways.</p><p>We speculate that 426c-based immunogens are able to bind germline precursors of VRC01-class bNAbs as a complete gp120 core because they can engage the unbound conformation of these Abs. This may allow the gp120-based immunogens to overcome a loss of binding affinity due to slow on-rates in the context of the already weak binding affinities of immature B cell receptors. The improved binding of the 426c-based gp120 immunogens to some germline VRC01-class Abs upon removal of the V1V2 and V3 loops from the 426c.TM1△V1-3 and 426c.TM4△V1-3 gp120s could result from the removal of steric occlusion by the variable loops (also not present in the eOD immunogens (<xref ref-type="bibr" rid="bib20">Jardine et al., 2013</xref>; <xref ref-type="bibr" rid="bib21">2015</xref>), and which may be flexible in the context of a gp120 or eOD), removal of glycans attached to these loops, or a combination of these factors. Thus, our results suggest implementation of a general strategy in which a germline-binding antigen is designed to be electrostatically compatible with the neutral or negatively charged antigen-binding surfaces of germline VRC01 Fabs and to fit in lock-and-key mode to the combining site of a germline Fab, with consideration paid to the slightly different angles of approach reported here for germline Fab binding to the gp120-based immunogens. The general principles established here for germline VRC01-class recognition of gp120 can be used to guide efforts to design and produce immunogens capable of eliciting broad and potent CD4bs Abs of the VRC01 class in uninfected people, facilitating the development of an efficacious vaccine to protect from HIV-1 infection.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Protein expression and purification</title><p>NIH45-46<sub>GL</sub> and 3BNC60<sub>GL</sub> were constructed as described previously by using the VH1-2*02 germline V gene segment, the appropriate germline V<sub>L</sub> gene segment, and mature sequences for CDRH3 and CDRL3 (<xref ref-type="bibr" rid="bib40">Scharf et al., 2013</xref>; <xref ref-type="bibr" rid="bib19">Hoot et al., 2013</xref>; <xref ref-type="bibr" rid="bib31">McGuire et al., 2013</xref>; <xref ref-type="bibr" rid="bib11">Dosenovic et al., 2015</xref>). The Abs were expressed and purified as described (<xref ref-type="bibr" rid="bib40">Scharf et al., 2013</xref>). Briefly, IgGs and 6xHis-tagged Fab fragments were produced by transient cotransfection of appropriate HC and LC plasmids into HEK293-6E cells followed by purification of the secreted proteins from cell supernatant using protein A (GE Healthcare; Pittsburg, PA) or Ni-NTA (GE Healthcare) affinity chromatography and Superdex 200 16/60 (GE Healthcare) size exclusion chromatography (SEC). gp120 proteins were expressed as cores with N/C termini and V1-V2 and V3 loop truncations as described for previous structural studies (<xref ref-type="bibr" rid="bib52">Zhou et al., 2010</xref>) by transient transfection of suspension-adapted HEK293-S cells. gp120s were purified using Ni-NTA affinity chromatography and Superdex 200 16/60 SEC. Proteins were stored in 20 mM Tris, pH 8.0, and 150 mM sodium chloride (TBS buffer) supplemented with 0.02% (wt/vol) NaN<sub>3</sub>.</p></sec><sec id="s4-2"><title>Crystallization</title><p>Crystals of 3BNC60<sub>GL</sub> Fab were obtained by combining 0.2 μL of a 15 mg/mL protein solution with 0.2 μL of 0.1 M bicine pH 9.1 and 10% (w/v) PEG 1,500 at 20°C and cryoprotected in mother liquor supplemented with 20% (v/v) glycerol. Crystals of 426c.TM4△V1-3 gp120 were obtained by combining 0.2 μL of a 10 mg/mL protein solution with 0.2 μL of 0.1 M sodium citrate tribasic dihydrate pH 5.0, 10% (w/v) PEG 6000 and 0.2 M sodium thiocyanate at 20°C and cryoprotected in mother liquor supplemented with 30% (v/v) 2-propanol. Complexes of 3BNC60<sub>GL</sub>/426c.TM4△V1-3, NIH45-46<sub>GL</sub>/426c.TM1△V1-3 and 3BNC55<sub>MAT</sub>/426c.TM4△V1-3 were produced by incubating Fabs and gp120s at a 3:1 molar ratio at 4°C for 16 hrs, followed by Endoglycosidase H (New England BioLabs; <ext-link ext-link-type="uri" xlink:href="https://www.google.com/search?q=Ipswich+Massachusetts&amp;stick=H4sIAAAAAAAAAOPgE-LSz9U3MDKvyMoyV-IEsQ1zzQsqtbSyk63084vSE_MyqxJLMvPzUDhWGamJKYWliUUlqUXFAHZQROBFAAAA&amp;sa=X&amp;ved=0ahUKEwiD-PTRmMbLAhVCy2MKHXLwCD0QmxMIhQEoATAR">Ipswich, MA</ext-link>) treatment and SEC purification. Fractions containing complexes were combined and concentrated as indicated below. Crystals of 3BNC60<sub>GL</sub>/426c.TM4△V1-3 complex were obtained by combining 0.2 μL of a 20 mg/mL protein solution with 0.2 μL of 0.1 M imidazole pH 7.0, 8% (w/v) PEG10000, 10 mM calcium chloride dihydrate at 20°C and cryoprotected in mother liquor supplemented with 20% (w/v) ethylene glycol. Crystals of NIH45-46<sub>GL</sub>/426c.TM1△V1-3 complex were obtained by combining 0.2 μL of a 20 mg/mL protein solution with 0.2 μL of 0.1 M sodium citrate pH 5.5, 22% (w/v) PEG 1000, 3% (w/v) xylitol at 20°C and cryoprotected in mother liquor supplemented with 20% (w/v) ethylene glycol. Crystals of 3BNC55<sub>MAT</sub>/426c.TM4△V1-3 complex were obtained by combining 0.2 μL of a 15 mg/mL protein solution with 0.2 μL of 0.1 M sodium citrate pH 5.5, 18% (w/v) PEG 1,000, 3% (w/v) ethylene glycol at 20°C and cryoprotected in mother liquor supplemented with 20% (w/v) ethylene glycol. All crystals were flash cooled in liquid nitrogen.</p></sec><sec id="s4-3"><title>Data collection and structure determination</title><p>X-ray diffraction data were collected at the Stanford Synchrotron Radiation Lightsource beamline 12–2 outfitted with a Pilatus 6M pixel detector (Dectris; Baden-Dättwil, Switzerland). XDS was used to index, integrate and scale the data (<xref ref-type="bibr" rid="bib22">Kabsch, 2010</xref>). The structures were refined using an iterative approach of refinement with Phenix (<xref ref-type="bibr" rid="bib1">Adams et al., 2010</xref>) and manual model building in Coot (<xref ref-type="bibr" rid="bib12">Emsley and Cowtan, 2004</xref>). Crystals of 3BNC60<sub>GL</sub> Fab (one molecule per asymmetric unit) diffracted to 1.9 Å, and the structure was solved by molecular replacement using 3BNC117<sub>MAT</sub> Fab (PDB code 4JPV) V<sub>H</sub>V<sub>L</sub> with CDR loops removed and C<sub>H</sub>1C<sub>L</sub> as search models. The final model (R<sub>work</sub> = 19.6%, R<sub>free</sub> = 21.0%) has 99%, 1%, and 0% of residues in the favored, allowed and disallowed regions, respectively, of the Ramachandran plot. Crystals of NIH45-46<sub>GL</sub>/426c.TM1△V1-3 complex (one Fab-gp120 complex per asymmetric unit) diffracted to 3.4 Å, and the structure was solved by molecular replacement using 93TH057 gp120 core (PDB code 4JDT) and NIH45-46<sub>GL</sub> Fab V<sub>H</sub>V<sub>L</sub> with CDR loops removed and C<sub>H</sub>1C<sub>L</sub> (from PDB code 4JDV) as the search models. The final model (R<sub>work</sub> = 27.9%, R<sub>free</sub> = 28.6%) has 95.7%, 4.3% and 0% of residues in the favored, allowed, and disallowed regions, respectively, of the Ramachandran plot. Some parts of the C<sub>H</sub>1C<sub>L</sub> domain were not well ordered in the electron density, probably because this domain did not make crystal packing contacts. To account for regions of disorder, unresolved C<sub>H</sub>1C<sub>L</sub> residues were assigned occupancies of 0. Crystals of 426c.TM4△V1-3 gp120 diffracted to 2.0 Å, contained two molecules in the asymmetric unit and the structure was solved by molecular replacement using 426c.TM1△V1-3 as the search model. The final model (R<sub>work</sub> = 20.7%, R<sub>free</sub> = 23.2%) has 97.7%, 2.3% and 0% of residues in the favored, allowed, and disallowed regions, respectively, of the Ramachandran plot. Crystals of 3BNC60<sub>GL</sub>/426c.TM4△V1-3 complex diffracted to 3.1 Å, contained two Fab-gp120 complexes and two unbound gp120 molcules in the asymmetric unit and the structure was solved by molecular replacement using 426c.TM4△V1-3 gp120 core and 3BNC60<sub>GL</sub> Fab V<sub>H</sub>V<sub>L</sub> and C<sub>H</sub>1C<sub>L</sub> with CDR loops removed as the search models. The final model (R<sub>work</sub> = 20.3%, R<sub>free</sub> = 26.7%) has 97%, 2.9% and 0.1% of residues in the favored, allowed and disallowed regions, respectively, of the Ramachandran plot. Crystals of 3BNC55<sub>MAT</sub>/ 426c.TM4△V1-3 complex diffracted to 3.0 Å, contained two Fab-gp120 complexes in the asymmetric unit and the structure was solved by molecular replacement using 426c.TM4△V1-3 gp120 core and 3BNC117<sub>MAT</sub> Fab (from PDB code 4JPV) V<sub>H</sub>V<sub>L</sub> and C<sub>H</sub>1C<sub>L</sub> with CDR loops removed as the search models. The final model (R<sub>work</sub> = 24.0%, R<sub>free</sub> = 27.9%) has 98%, 1.7%, and 0.3% of residues in the favored, allowed, and disallowed regions, respectively, of the Ramachandran plot.</p><p>Buried surface areas were calculated using PDBePISA (<xref ref-type="bibr" rid="bib25">Krissinel and Henrick, 2007</xref>) and a 1.4 Å probe. Hydrogen bonds were assigned tentatively due to the low resolution of the complex structures using the following criteria: a distance of &lt;3.5 Å, and an A-D-H angle of &gt;90°. Structures were superimposed and molecular representations were generated with PyMOL (<xref ref-type="bibr" rid="bib42">Schrödinger LLC, 2011</xref>) and UCSF Chimera (<xref ref-type="bibr" rid="bib37">Pettersen et al., 2004</xref>). Rmsd calculations following pairwise Cα alignments were done in PyMOL without outlier rejection.</p></sec><sec id="s4-4"><title>SPR experiments</title><p>All SPR measurements were performed on a Biacore T200 (GE Healthcare) at 20°C using HBS-EP+ (GE Healthcare) as the running buffer. A CM5 chip (GE Healthcare) containing 3000 resonance units (RUs) of primary amine-coupled protein A (Pierce; Waltham, MA) was used to capture HIV-1 IgGs (3BNC60<sub>GL</sub>, NIH45-46<sub>GL</sub>, VRC01<sub>GL</sub>, 3BNC60<sub>MAT</sub>, NIH45-46<sub>MAT</sub>) and a non-gp120-binding control IgG (mG053) by injecting 0.25 μg/mL or 0.1 μg/mL solutions of germline or mature IgG, respectively. Remaining protein A binding sites were blocked by injecting 1 μM Fc. gp120 cores (426c.TM1△V1-3, 426c.TM4△V1-3, 93TH057) were injected over the flow cells at increasing concentrations (top concentration of 16 μM for germline Abs, 200 nM for mature Abs) at a flow rate of 50 μL/min for 240 s and allowed to dissociate for 500 sec. Regeneration of flow cells was achieved by injecting one pulse each of 10 mM glycine pH 2 and 1 M guanidine-HCl at a flow rate of 90 μL/min. Kinetic analyses were used after subtraction of reference curves to derive on/off rates (<italic>k</italic><sub>a</sub>/<italic>k</italic><sub>d</sub>) and binding constants (<italic>K</italic><sub>D</sub>s) with a 1:1 binding model with or without bulk refractive index change (RI) correction as appropriate (Biacore T200 Evaluation software).</p></sec><sec id="s4-5"><title>Antibody approach angle comparisons</title><p>The VRC01<sub>MAT</sub>/93TH057 gp120 complex (PDB code 3NGB) was used as the reference structure for comparisons of angles of approach of Fab recognition of gp120s (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). The center of mass of the VRC01 V<sub>H</sub> domain was placed at the origin and its principal axes of inertia were aligned with the Cartesian axes using AMORE from the CCP4 program suite (<xref ref-type="bibr" rid="bib6">CCP4, 1994</xref>). The 3NGB complex was then aligned with the centered V<sub>H</sub> domain. For comparisons with other complexes, each Fab/gp120 complex was aligned with the 3NGB gp120 chain using LSQMAN (<xref ref-type="bibr" rid="bib24">Kleywegt, 1996</xref>). The transformation matrix between the aligned Fab/gp120 V<sub>H</sub> domain and the VRC01 V<sub>H</sub> domain was then calculated by LSQMAN.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank the Caltech Protein Expression Center for producing antibody and gp120 proteins, generation of suspension-adapted HEK293-S cells and use of the Biacore T200. Operations at the Stanford Synchrotron Radiation Lightsource are supported by the US Department of Energy and the National Institutes of Health. MCN is a Howard Hughes Medical Institute investigator. This research was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health Grant HIVRAD P01 AI100148 (PJB and MCN); (the content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health), Collaboration for AIDS Vaccine Discovery grants from The Bill and Melinda Gates Foundation (grant IDs 1040753 to PJB and 1124068 to MCN), the American Cancer Society (Grant PF-13-076-01-MPC to LS), and the California HIV/AIDS Research Program (CHRP grant F12-CT-214 to SAS).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf2"><p>MCN: Reviewing editor, <italic>eLife.</italic></p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>LSc, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con2"><p>APW, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con3"><p>SAS, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con4"><p>CC, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con5"><p>SJ, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con6"><p>HG, Acquisition of data, Contributed unpublished essential data or reagents</p></fn><fn fn-type="con" id="con7"><p>MDG, Contributed unpublished essential data or reagents</p></fn><fn fn-type="con" id="con8"><p>ATM, Drafting or revising the article, Contributed unpublished essential data or reagents</p></fn><fn fn-type="con" id="con9"><p>JFS, Contributed unpublished essential data or reagents</p></fn><fn fn-type="con" id="con10"><p>MCN, Drafting or revising the article, Contributed unpublished essential data or reagents</p></fn><fn fn-type="con" id="con11"><p>LSt, Drafting or revising the article, Contributed unpublished essential data or reagents</p></fn><fn fn-type="con" id="con12"><p>PJB, Conception and design, Analysis and interpretation of data, Drafting or revising the article</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="SD2-data"><object-id pub-id-type="doi">10.7554/eLife.13783.015</object-id><label>Supplementary file 1.</label><caption><title>Interfaces in NIH45-46<sub>GL</sub>-426c.TM1ΔV1-3 and 3BNC60<sub>GL</sub>-426c.TM4ΔV1-3 Complexes.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.13783.015">http://dx.doi.org/10.7554/eLife.13783.015</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-13783-supp1-v1.xlsx"/></supplementary-material><sec id="s7" sec-type="datasets"><title>Major datasets</title><p>The following datasets were generated:</p><p><related-object content-type="generated-dataset" id="dataro1" source-id="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F7E" source-id-type="uri"><collab>Scharf L</collab>, <collab>Sievers SA</collab>, <collab>Jiang S</collab>, <collab>Bjorkman PJ</collab><x>,</x> <year>2015</year><x>,</x><source>Crystal structure of germ-line precursor of 3BNC60 Fab</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F7E">http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F7E</ext-link><x>,</x> <comment>Publicly available at the RCSB Protein Data Bank (accession no. 5F7E)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataro2" source-id="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FA2" source-id-type="uri"><collab>Scharf L</collab>, <collab>Bjorkman PJ</collab><x>,</x> <year>2015</year><x>,</x><source>Crystal structure of 426c.TM4deltaV1-3 gp120</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FA2">http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FA2</ext-link><x>,</x> <comment>Publicly available at the RCSB Protein Data Bank (accession no. 5FA2)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataro3" source-id="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FEC" source-id-type="uri"><collab>Scharf L</collab>, <collab>Bjorkman PJ</collab><x>,</x> <year>2015</year><x>,</x><source>Crystal structure of 3BNC60 Fab germline precursor in complex with 426c.TM4deltaV1-3 gp120</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FEC">http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FEC</ext-link><x>,</x> <comment>Publicly available at the RCSB Protein Data Bank (accession no. 5FEC)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataro4" source-id="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IGX" source-id-type="uri"><collab>Scharf L</collab>, <collab>Bjorkman PJ</collab><x>,</x> <year>2015</year><x>,</x><source>Crystal structure of NIH45-46 Fab germline precursor in complex with 426c.TM1deltaV1-3 gp120</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IGX">http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IGX</ext-link><x>,</x> <comment>Publicly available at the RCSB Protein Data Bank (accession no. 5IGX)</comment></related-object></p><p><related-object content-type="generated-dataset" id="dataro5" source-id="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5I9Q" source-id-type="uri"><collab>Scharf L</collab>, <collab>Chen C</collab>, <collab>Bjorkman PJ</collab><x>,</x> <year>2015</year><x>,</x><source>Crystal structure of 3BNC55 Fab in complex with 426c.TM4deltaV1-3 gp120</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5I9Q">http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5I9Q</ext-link><x>,</x> <comment>Publicly available at the RCSB Protein Data Bank (accession no. 5I90)</comment></related-object></p></sec></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Afonine</surname><given-names>PV</given-names></name><name><surname>Bunkóczi</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>VB</given-names></name><name><surname>Davis</surname><given-names>IW</given-names></name><name><surname>Echols</surname><given-names>N</given-names></name><name><surname>Headd</surname><given-names>JJ</given-names></name><name><surname>Hung</surname><given-names>LW</given-names></name><name><surname>Kapral</surname><given-names>GJ</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>RW</given-names></name><name><surname>McCoy</surname><given-names>AJ</given-names></name><name><surname>Moriarty</surname><given-names>NW</given-names></name><name><surname>Oeffner</surname><given-names>R</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name><name><surname>Richardson</surname><given-names>DC</given-names></name><name><surname>Richardson</surname><given-names>JS</given-names></name><name><surname>Terwilliger</surname><given-names>TC</given-names></name><name><surname>Zwart</surname><given-names>PH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PHENIX: a comprehensive Python-based system for macromolecular structure solution</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1107/S0907444909052925</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batista</surname><given-names>FD</given-names></name><name><surname>Neuberger</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Affinity dependence of the B Cell response to antigen: A threshold, a ceiling, and the importance of off-rate</article-title><source>Immunity</source><volume>8</volume><fpage>751</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(00)80580-4</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behrens</surname><given-names>AJ</given-names></name><name><surname>Vasiljevic</surname><given-names>S</given-names></name><name><surname>Pritchard</surname><given-names>LK</given-names></name><name><surname>Harvey</surname><given-names>DJ</given-names></name><name><surname>Andev</surname><given-names>RS</given-names></name><name><surname>Krumm</surname><given-names>SA</given-names></name><name><surname>Struwe</surname><given-names>WB</given-names></name><name><surname>Cupo</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Zitzmann</surname><given-names>N</given-names></name><name><surname>Seabright</surname><given-names>GE</given-names></name><name><surname>Kramer</surname><given-names>HB</given-names></name><name><surname>Spencer</surname><given-names>DI</given-names></name><name><surname>Royle</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Klasse</surname><given-names>PJ</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Sanders</surname><given-names>RW</given-names></name><name><surname>Moore</surname><given-names>JP</given-names></name><name><surname>Doores</surname><given-names>KJ</given-names></name><name><surname>Crispin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein</article-title><source>Cell Reports</source><pub-id pub-id-type="doi">10.1016/j.celrep.2016.02.058</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binley</surname><given-names>JM</given-names></name><name><surname>Ban</surname><given-names>YE</given-names></name><name><surname>Crooks</surname><given-names>ET</given-names></name><name><surname>Eggink</surname><given-names>D</given-names></name><name><surname>Osawa</surname><given-names>K</given-names></name><name><surname>Schief</surname><given-names>WR</given-names></name><name><surname>Sanders</surname><given-names>RW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization</article-title><source>Journal of Virology</source><volume>84</volume><fpage>5637</fpage><lpage>5655</lpage><pub-id pub-id-type="doi">10.1128/JVI.00105-10</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackler</surname><given-names>RJ</given-names></name><name><surname>Müller-Loennies</surname><given-names>S</given-names></name><name><surname>Brooks</surname><given-names>CL</given-names></name><name><surname>Evans</surname><given-names>DW</given-names></name><name><surname>Brade</surname><given-names>L</given-names></name><name><surname>Kosma</surname><given-names>P</given-names></name><name><surname>Brade</surname><given-names>H</given-names></name><name><surname>Evans</surname><given-names>SV</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A common NH53K mutation in the combining site of antibodies raised against chlamydial LPS glycoconjugates significantly increases avidity</article-title><source>Biochemistry</source><volume>50</volume><fpage>3357</fpage><lpage>3368</lpage><pub-id pub-id-type="doi">10.1021/bi101886v</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>CCP4</collab></person-group><year iso-8601-date="1994">1994</year><article-title>The CCP4 suite: programs for protein crystallography</article-title><source>Acta Crystallographica</source><volume>50 (Pt 5)</volume><fpage>760</fpage><lpage>763</lpage></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caskey</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Lorenzi</surname><given-names>JC</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>West</surname><given-names>AP</given-names></name><name><surname>Buckley</surname><given-names>N</given-names></name><name><surname>Kremer</surname><given-names>G</given-names></name><name><surname>Nogueira</surname><given-names>L</given-names></name><name><surname>Braunschweig</surname><given-names>M</given-names></name><name><surname>Scheid</surname><given-names>JF</given-names></name><name><surname>Horwitz</surname><given-names>JA</given-names></name><name><surname>Shimeliovich</surname><given-names>I</given-names></name><name><surname>Ben-Avraham</surname><given-names>S</given-names></name><name><surname>Witmer-Pack</surname><given-names>M</given-names></name><name><surname>Platten</surname><given-names>M</given-names></name><name><surname>Lehmann</surname><given-names>C</given-names></name><name><surname>Burke</surname><given-names>LA</given-names></name><name><surname>Hawthorne</surname><given-names>T</given-names></name><name><surname>Gorelick</surname><given-names>RJ</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name><name><surname>Keler</surname><given-names>T</given-names></name><name><surname>Gulick</surname><given-names>RM</given-names></name><name><surname>Fätkenheuer</surname><given-names>G</given-names></name><name><surname>Schlesinger</surname><given-names>SJ</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117</article-title><source>Nature</source><volume>522</volume><pub-id pub-id-type="doi">10.1038/nature14411</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diskin</surname><given-names>R</given-names></name><name><surname>Scheid</surname><given-names>JF</given-names></name><name><surname>Marcovecchio</surname><given-names>PM</given-names></name><name><surname>West</surname><given-names>AP</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Gnanapragasam</surname><given-names>PN</given-names></name><name><surname>Abadir</surname><given-names>A</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Increasing the potency and breadth of an HIV antibody by using structure-based rational design</article-title><source>Science</source><volume>334</volume><fpage>1289</fpage><lpage>1293</lpage><pub-id pub-id-type="doi">10.1126/science.1213782</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diskin</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Horwitz</surname><given-names>JA</given-names></name><name><surname>Halper-Stromberg</surname><given-names>A</given-names></name><name><surname>Sather</surname><given-names>DN</given-names></name><name><surname>Marcovecchio</surname><given-names>PM</given-names></name><name><surname>Lee</surname><given-names>T</given-names></name><name><surname>West</surname><given-names>AP</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Stamatatos</surname><given-names>L</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies</article-title><source>The Journal of Experimental Medicine</source><volume>210</volume><fpage>1235</fpage><lpage>1249</lpage><pub-id pub-id-type="doi">10.1084/jem.20130221</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doria-Rose</surname><given-names>NA</given-names></name><name><surname>Schramm</surname><given-names>CA</given-names></name><name><surname>Gorman</surname><given-names>J</given-names></name><name><surname>Moore</surname><given-names>PL</given-names></name><name><surname>Bhiman</surname><given-names>JN</given-names></name><name><surname>DeKosky</surname><given-names>BJ</given-names></name><name><surname>Ernandes</surname><given-names>MJ</given-names></name><name><surname>Georgiev</surname><given-names>IS</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Pancera</surname><given-names>M</given-names></name><name><surname>Staupe</surname><given-names>RP</given-names></name><name><surname>Altae-Tran</surname><given-names>HR</given-names></name><name><surname>Bailer</surname><given-names>RT</given-names></name><name><surname>Crooks</surname><given-names>ET</given-names></name><name><surname>Cupo</surname><given-names>A</given-names></name><name><surname>Druz</surname><given-names>A</given-names></name><name><surname>Garrett</surname><given-names>NJ</given-names></name><name><surname>Hoi</surname><given-names>KH</given-names></name><name><surname>Kong</surname><given-names>R</given-names></name><name><surname>Louder</surname><given-names>MK</given-names></name><name><surname>Longo</surname><given-names>NS</given-names></name><name><surname>McKee</surname><given-names>K</given-names></name><name><surname>Nonyane</surname><given-names>M</given-names></name><name><surname>O'Dell</surname><given-names>S</given-names></name><name><surname>Roark</surname><given-names>RS</given-names></name><name><surname>Rudicell</surname><given-names>RS</given-names></name><name><surname>Schmidt</surname><given-names>SD</given-names></name><name><surname>Sheward</surname><given-names>DJ</given-names></name><name><surname>Soto</surname><given-names>C</given-names></name><name><surname>Wibmer</surname><given-names>CK</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Mullikin</surname><given-names>JC</given-names></name><name><surname>Binley</surname><given-names>JM</given-names></name><name><surname>Sanders</surname><given-names>RW</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name><name><surname>Moore</surname><given-names>JP</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Georgiou</surname><given-names>G</given-names></name><name><surname>Williamson</surname><given-names>C</given-names></name><name><surname>Abdool Karim</surname><given-names>SS</given-names></name><name><surname>Morris</surname><given-names>L</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name><name><surname>Shapiro</surname><given-names>L</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><collab>NISC Comparative Sequencing Program</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies</article-title><source>Nature</source><volume>509</volume><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1038/nature13036</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dosenovic</surname><given-names>P</given-names></name><name><surname>von Boehmer</surname><given-names>L</given-names></name><name><surname>Escolano</surname><given-names>A</given-names></name><name><surname>Jardine</surname><given-names>J</given-names></name><name><surname>Freund</surname><given-names>NT</given-names></name><name><surname>Gitlin</surname><given-names>AD</given-names></name><name><surname>McGuire</surname><given-names>AT</given-names></name><name><surname>Kulp</surname><given-names>DW</given-names></name><name><surname>Oliveira</surname><given-names>T</given-names></name><name><surname>Scharf</surname><given-names>L</given-names></name><name><surname>Pietzsch</surname><given-names>J</given-names></name><name><surname>Gray</surname><given-names>MD</given-names></name><name><surname>Cupo</surname><given-names>A</given-names></name><name><surname>van Gils</surname><given-names>MJ</given-names></name><name><surname>Yao</surname><given-names>KH</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Gazumyan</surname><given-names>A</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Björkman</surname><given-names>PJ</given-names></name><name><surname>Sanders</surname><given-names>RW</given-names></name><name><surname>Moore</surname><given-names>JP</given-names></name><name><surname>Stamatatos</surname><given-names>L</given-names></name><name><surname>Schief</surname><given-names>WR</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice</article-title><source>Cell</source><volume>161</volume><fpage>1505</fpage><lpage>1515</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.06.003</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P</given-names></name><name><surname>Cowtan</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Coot: model-building tools for molecular graphics</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>60</volume><fpage>2126</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.1107/S0907444904019158</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fera</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>AG</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Liao</surname><given-names>HX</given-names></name><name><surname>Kepler</surname><given-names>TB</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>111</volume><fpage>10275</fpage><lpage>10280</lpage><pub-id pub-id-type="doi">10.1073/pnas.1409954111</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finton</surname><given-names>KA</given-names></name><name><surname>Friend</surname><given-names>D</given-names></name><name><surname>Jaffe</surname><given-names>J</given-names></name><name><surname>Gewe</surname><given-names>M</given-names></name><name><surname>Holmes</surname><given-names>MA</given-names></name><name><surname>Larman</surname><given-names>HB</given-names></name><name><surname>Stuart</surname><given-names>A</given-names></name><name><surname>Larimore</surname><given-names>K</given-names></name><name><surname>Greenberg</surname><given-names>PD</given-names></name><name><surname>Elledge</surname><given-names>SJ</given-names></name><name><surname>Stamatatos</surname><given-names>L</given-names></name><name><surname>Strong</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10</article-title><source>PLoS Pathogens</source><volume>10</volume><elocation-id>e1004403</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004403</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foote</surname><given-names>J</given-names></name><name><surname>Milstein</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Conformational isomerism and the diversity of antibodies</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>91</volume><fpage>10370</fpage><lpage>10374</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.22.10370</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garces</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>de Val</surname><given-names>N</given-names></name><name><surname>Torrents de la Pena</surname><given-names>A</given-names></name><name><surname>Kong</surname><given-names>L</given-names></name><name><surname>Puchades</surname><given-names>C</given-names></name><name><surname>Hua</surname><given-names>Y</given-names></name><name><surname>Stanfield</surname><given-names>RL</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Moore</surname><given-names>JP</given-names></name><name><surname>Sanders</surname><given-names>RW</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans</article-title><source>Immunity</source><volume>43</volume><fpage>1053</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.11.007</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgiev</surname><given-names>IS</given-names></name><name><surname>Doria-Rose</surname><given-names>NA</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Kwon</surname><given-names>YD</given-names></name><name><surname>Staupe</surname><given-names>RP</given-names></name><name><surname>Moquin</surname><given-names>S</given-names></name><name><surname>Chuang</surname><given-names>GY</given-names></name><name><surname>Louder</surname><given-names>MK</given-names></name><name><surname>Schmidt</surname><given-names>SD</given-names></name><name><surname>Altae-Tran</surname><given-names>HR</given-names></name><name><surname>Bailer</surname><given-names>RT</given-names></name><name><surname>McKee</surname><given-names>K</given-names></name><name><surname>Nason</surname><given-names>M</given-names></name><name><surname>O'Dell</surname><given-names>S</given-names></name><name><surname>Ofek</surname><given-names>G</given-names></name><name><surname>Pancera</surname><given-names>M</given-names></name><name><surname>Srivatsan</surname><given-names>S</given-names></name><name><surname>Shapiro</surname><given-names>L</given-names></name><name><surname>Connors</surname><given-names>M</given-names></name><name><surname>Migueles</surname><given-names>SA</given-names></name><name><surname>Morris</surname><given-names>L</given-names></name><name><surname>Nishimura</surname><given-names>Y</given-names></name><name><surname>Martin</surname><given-names>MA</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization</article-title><source>Science</source><volume>340</volume><fpage>751</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1126/science.1233989</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Go</surname><given-names>EP</given-names></name><name><surname>Hewawasam</surname><given-names>G</given-names></name><name><surname>Liao</surname><given-names>HX</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Ping</surname><given-names>LH</given-names></name><name><surname>Anderson</surname><given-names>JA</given-names></name><name><surname>Hua</surname><given-names>DC</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Desaire</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry</article-title><source>Journal of Virology</source><volume>85</volume><fpage>8270</fpage><lpage>8284</lpage><pub-id pub-id-type="doi">10.1128/JVI.05053-11</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoot</surname><given-names>S</given-names></name><name><surname>McGuire</surname><given-names>AT</given-names></name><name><surname>Cohen</surname><given-names>KW</given-names></name><name><surname>Strong</surname><given-names>RK</given-names></name><name><surname>Hangartner</surname><given-names>L</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Diskin</surname><given-names>R</given-names></name><name><surname>Scheid</surname><given-names>JF</given-names></name><name><surname>Sather</surname><given-names>DN</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Stamatatos</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs</article-title><source>PLoS Pathogens</source><volume>9</volume><elocation-id>e1003106</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003106</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jardine</surname><given-names>J</given-names></name><name><surname>Julien</surname><given-names>JP</given-names></name><name><surname>Menis</surname><given-names>S</given-names></name><name><surname>Ota</surname><given-names>T</given-names></name><name><surname>Kalyuzhniy</surname><given-names>O</given-names></name><name><surname>McGuire</surname><given-names>A</given-names></name><name><surname>Sok</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>PS</given-names></name><name><surname>MacPherson</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Nieusma</surname><given-names>T</given-names></name><name><surname>Mathison</surname><given-names>J</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Stamatatos</surname><given-names>L</given-names></name><name><surname>Nemazee</surname><given-names>D</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name><name><surname>Schief</surname><given-names>WR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Rational HIV immunogen design to target specific germline B cell receptors</article-title><source>Science</source><volume>340</volume><fpage>711</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1126/science.1234150</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jardine</surname><given-names>JG</given-names></name><name><surname>Ota</surname><given-names>T</given-names></name><name><surname>Sok</surname><given-names>D</given-names></name><name><surname>Pauthner</surname><given-names>M</given-names></name><name><surname>Kulp</surname><given-names>DW</given-names></name><name><surname>Kalyuzhniy</surname><given-names>O</given-names></name><name><surname>Skog</surname><given-names>PD</given-names></name><name><surname>Thinnes</surname><given-names>TC</given-names></name><name><surname>Bhullar</surname><given-names>D</given-names></name><name><surname>Briney</surname><given-names>B</given-names></name><name><surname>Menis</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>M</given-names></name><name><surname>Kubitz</surname><given-names>M</given-names></name><name><surname>Spencer</surname><given-names>S</given-names></name><name><surname>Adachi</surname><given-names>Y</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Schief</surname><given-names>WR</given-names></name><name><surname>Nemazee</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen</article-title><source>Science</source><volume>349</volume><fpage>156</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1126/science.aac5894</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabsch</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>XDS</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1107/S0907444909047337</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Diskin</surname><given-names>R</given-names></name><name><surname>Scheid</surname><given-names>JF</given-names></name><name><surname>Gaebler</surname><given-names>C</given-names></name><name><surname>Mouquet</surname><given-names>H</given-names></name><name><surname>Georgiev</surname><given-names>IS</given-names></name><name><surname>Pancera</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Incesu</surname><given-names>RB</given-names></name><name><surname>Fu</surname><given-names>BZ</given-names></name><name><surname>Gnanapragasam</surname><given-names>PN</given-names></name><name><surname>Oliveira</surname><given-names>TY</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization</article-title><source>Cell</source><volume>153</volume><fpage>126</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.03.018</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleywegt</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Use of non-crystallographic symmetry in protein structure refinement</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>52</volume><fpage>842</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1107/S0907444995016477</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krissinel</surname><given-names>E</given-names></name><name><surname>Henrick</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Inference of macromolecular assemblies from crystalline state</article-title><source>Journal of Molecular Biology</source><volume>372</volume><fpage>774</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2007.05.022</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwong</surname><given-names>PD</given-names></name><name><surname>Wyatt</surname><given-names>R</given-names></name><name><surname>Robinson</surname><given-names>J</given-names></name><name><surname>Sweet</surname><given-names>RW</given-names></name><name><surname>Sodroski</surname><given-names>J</given-names></name><name><surname>Hendrickson</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody</article-title><source>Nature</source><volume>393</volume><fpage>648</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1038/31405</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwong</surname><given-names>PD</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies</article-title><source>Immunity</source><volume>37</volume><fpage>412</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.08.012</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Huey-Tubman</surname><given-names>KE</given-names></name><name><surname>Gao</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>West</surname><given-names>AP</given-names></name><name><surname>Bennett</surname><given-names>MJ</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The structure of a polyQ-anti-polyQ complex reveals binding according to a linear lattice model</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>14</volume><fpage>381</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1038/nsmb1234</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>HX</given-names></name><name><surname>Bonsignori</surname><given-names>M</given-names></name><name><surname>Alam</surname><given-names>SM</given-names></name><name><surname>McLellan</surname><given-names>JS</given-names></name><name><surname>Tomaras</surname><given-names>GD</given-names></name><name><surname>Moody</surname><given-names>MA</given-names></name><name><surname>Kozink</surname><given-names>DM</given-names></name><name><surname>Hwang</surname><given-names>KK</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Tsao</surname><given-names>CY</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Parks</surname><given-names>RJ</given-names></name><name><surname>Montefiori</surname><given-names>DC</given-names></name><name><surname>Ferrari</surname><given-names>G</given-names></name><name><surname>Pollara</surname><given-names>J</given-names></name><name><surname>Rao</surname><given-names>M</given-names></name><name><surname>Peachman</surname><given-names>KK</given-names></name><name><surname>Santra</surname><given-names>S</given-names></name><name><surname>Letvin</surname><given-names>NL</given-names></name><name><surname>Karasavvas</surname><given-names>N</given-names></name><name><surname>Yang</surname><given-names>ZY</given-names></name><name><surname>Dai</surname><given-names>K</given-names></name><name><surname>Pancera</surname><given-names>M</given-names></name><name><surname>Gorman</surname><given-names>J</given-names></name><name><surname>Wiehe</surname><given-names>K</given-names></name><name><surname>Nicely</surname><given-names>NI</given-names></name><name><surname>Rerks-Ngarm</surname><given-names>S</given-names></name><name><surname>Nitayaphan</surname><given-names>S</given-names></name><name><surname>Kaewkungwal</surname><given-names>J</given-names></name><name><surname>Pitisuttithum</surname><given-names>P</given-names></name><name><surname>Tartaglia</surname><given-names>J</given-names></name><name><surname>Sinangil</surname><given-names>F</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Michael</surname><given-names>NL</given-names></name><name><surname>Kepler</surname><given-names>TB</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name><name><surname>Pinter</surname><given-names>A</given-names></name><name><surname>Zolla-Pazner</surname><given-names>S</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2</article-title><source>Immunity</source><volume>38</volume><fpage>176</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.11.011</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Wiehe</surname><given-names>K</given-names></name><name><surname>Nicely</surname><given-names>NI</given-names></name><name><surname>Vandergrift</surname><given-names>NA</given-names></name><name><surname>Rountree</surname><given-names>W</given-names></name><name><surname>Bonsignori</surname><given-names>M</given-names></name><name><surname>Alam</surname><given-names>SM</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Kelsoe</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Polyreactivity and autoreactivity among HIV-1 antibodies</article-title><source>Journal of Virology</source><volume>89</volume><fpage>784</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1128/JVI.02378-14</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGuire</surname><given-names>AT</given-names></name><name><surname>Hoot</surname><given-names>S</given-names></name><name><surname>Dreyer</surname><given-names>AM</given-names></name><name><surname>Lippy</surname><given-names>A</given-names></name><name><surname>Stuart</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>KW</given-names></name><name><surname>Jardine</surname><given-names>J</given-names></name><name><surname>Menis</surname><given-names>S</given-names></name><name><surname>Scheid</surname><given-names>JF</given-names></name><name><surname>West</surname><given-names>AP</given-names></name><name><surname>Schief</surname><given-names>WR</given-names></name><name><surname>Stamatatos</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies</article-title><source>The Journal of Experimental Medicine</source><volume>210</volume><fpage>655</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1084/jem.20122824</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGuire</surname><given-names>AT</given-names></name><name><surname>Dreyer</surname><given-names>AM</given-names></name><name><surname>Carbonetti</surname><given-names>S</given-names></name><name><surname>Lippy</surname><given-names>A</given-names></name><name><surname>Glenn</surname><given-names>J</given-names></name><name><surname>Scheid</surname><given-names>JF</given-names></name><name><surname>Mouquet</surname><given-names>H</given-names></name><name><surname>Stamatatos</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies</article-title><source>Science</source><volume>346</volume><fpage>1380</fpage><lpage>1383</lpage><pub-id pub-id-type="doi">10.1126/science.1259206</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGuire</surname><given-names>AT</given-names></name><name><surname>Gray</surname><given-names>MD</given-names></name><name><surname>Dosenovic</surname><given-names>P</given-names></name><name><surname>Gitlin</surname><given-names>AD</given-names></name><name><surname>Freund</surname><given-names>NT</given-names></name><name><surname>Petersen</surname><given-names>J</given-names></name><name><surname>Correnti</surname><given-names>C</given-names></name><name><surname>Johnsen</surname><given-names>W</given-names></name><name><surname>Kegel</surname><given-names>R</given-names></name><name><surname>Stuart</surname><given-names>AB</given-names></name><name><surname>Glenn</surname><given-names>J</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Schief</surname><given-names>WR</given-names></name><name><surname>Strong</surname><given-names>RK</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Stamatatos</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice</article-title><source>Nature Communications</source><volume>7</volume><fpage>10618</fpage><pub-id pub-id-type="doi">10.1038/ncomms10618</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouquet</surname><given-names>H</given-names></name><name><surname>Scheid</surname><given-names>JF</given-names></name><name><surname>Zoller</surname><given-names>MJ</given-names></name><name><surname>Krogsgaard</surname><given-names>M</given-names></name><name><surname>Ott</surname><given-names>RG</given-names></name><name><surname>Shukair</surname><given-names>S</given-names></name><name><surname>Artyomov</surname><given-names>MN</given-names></name><name><surname>Pietzsch</surname><given-names>J</given-names></name><name><surname>Connors</surname><given-names>M</given-names></name><name><surname>Pereyra</surname><given-names>F</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name><name><surname>Ho</surname><given-names>DD</given-names></name><name><surname>Wilson</surname><given-names>PC</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Eisen</surname><given-names>HN</given-names></name><name><surname>Chakraborty</surname><given-names>AK</given-names></name><name><surname>Hope</surname><given-names>TJ</given-names></name><name><surname>Ravetch</surname><given-names>JV</given-names></name><name><surname>Wardemann</surname><given-names>H</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation</article-title><source>Nature</source><volume>467</volume><fpage>591</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1038/nature09385</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicely</surname><given-names>NI</given-names></name><name><surname>Wiehe</surname><given-names>K</given-names></name><name><surname>Kepler</surname><given-names>TB</given-names></name><name><surname>Jaeger</surname><given-names>FH</given-names></name><name><surname>Dennison</surname><given-names>SM</given-names></name><name><surname>Rerks-Ngarm</surname><given-names>S</given-names></name><name><surname>Nitayaphan</surname><given-names>S</given-names></name><name><surname>Pitisuttithum</surname><given-names>P</given-names></name><name><surname>Kaewkungwal</surname><given-names>J</given-names></name><name><surname>Robb</surname><given-names>ML</given-names></name><name><surname>O'Connell</surname><given-names>RJ</given-names></name><name><surname>Michael</surname><given-names>NL</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Liao</surname><given-names>HX</given-names></name><name><surname>Munir Alam</surname><given-names>S</given-names></name><name><surname>Hwang</surname><given-names>KK</given-names></name><name><surname>Bonsignori</surname><given-names>M</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee</article-title><source>EBioMedicine</source><volume>2</volume><fpage>713</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2015.06.016</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ota</surname><given-names>T</given-names></name><name><surname>Doyle-Cooper</surname><given-names>C</given-names></name><name><surname>Cooper</surname><given-names>AB</given-names></name><name><surname>Huber</surname><given-names>M</given-names></name><name><surname>Falkowska</surname><given-names>E</given-names></name><name><surname>Doores</surname><given-names>KJ</given-names></name><name><surname>Hangartner</surname><given-names>L</given-names></name><name><surname>Le</surname><given-names>K</given-names></name><name><surname>Sok</surname><given-names>D</given-names></name><name><surname>Jardine</surname><given-names>J</given-names></name><name><surname>Lifson</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Poignard</surname><given-names>P</given-names></name><name><surname>Binley</surname><given-names>JM</given-names></name><name><surname>Chakrabarti</surname><given-names>BK</given-names></name><name><surname>Schief</surname><given-names>WR</given-names></name><name><surname>Wyatt</surname><given-names>RT</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Nemazee</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Anti-HIV B Cell lines as candidate vaccine biosensors</article-title><source>Journal of Immunology</source><volume>189</volume><fpage>4816</fpage><lpage>4824</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1202165</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>EF</given-names></name><name><surname>Goddard</surname><given-names>TD</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Couch</surname><given-names>GS</given-names></name><name><surname>Greenblatt</surname><given-names>DM</given-names></name><name><surname>Meng</surname><given-names>EC</given-names></name><name><surname>Ferrin</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>UCSF Chimera--a visualization system for exploratory research and analysis</article-title><source>Journal of Computational Chemistry</source><volume>25</volume><fpage>1605</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>O</given-names></name><name><surname>Chill</surname><given-names>J</given-names></name><name><surname>Sharon</surname><given-names>M</given-names></name><name><surname>Kessler</surname><given-names>N</given-names></name><name><surname>Mester</surname><given-names>B</given-names></name><name><surname>Zolla-Pazner</surname><given-names>S</given-names></name><name><surname>Anglister</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization</article-title><source>Biochemistry</source><volume>44</volume><fpage>7250</fpage><lpage>7258</lpage><pub-id pub-id-type="doi">10.1021/bi047387t</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubelt</surname><given-names>F</given-names></name><name><surname>Sievert</surname><given-names>V</given-names></name><name><surname>Knaust</surname><given-names>F</given-names></name><name><surname>Diener</surname><given-names>C</given-names></name><name><surname>Lim</surname><given-names>TS</given-names></name><name><surname>Skriner</surname><given-names>K</given-names></name><name><surname>Klipp</surname><given-names>E</given-names></name><name><surname>Reinhardt</surname><given-names>R</given-names></name><name><surname>Lehrach</surname><given-names>H</given-names></name><name><surname>Konthur</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Onset of immune senescence defined by unbiased pyrosequencing of human immunoglobulin mRNA repertoires</article-title><source>PloS One</source><volume>7</volume><elocation-id>e49774</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0049774</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scharf</surname><given-names>L</given-names></name><name><surname>West</surname><given-names>AP</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>T</given-names></name><name><surname>Scheid</surname><given-names>JF</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Diskin</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>110</volume><fpage>6049</fpage><lpage>6054</lpage><pub-id pub-id-type="doi">10.1073/pnas.1303682110</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheid</surname><given-names>JF</given-names></name><name><surname>Mouquet</surname><given-names>H</given-names></name><name><surname>Ueberheide</surname><given-names>B</given-names></name><name><surname>Diskin</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Oliveira</surname><given-names>TY</given-names></name><name><surname>Pietzsch</surname><given-names>J</given-names></name><name><surname>Fenyo</surname><given-names>D</given-names></name><name><surname>Abadir</surname><given-names>A</given-names></name><name><surname>Velinzon</surname><given-names>K</given-names></name><name><surname>Hurley</surname><given-names>A</given-names></name><name><surname>Myung</surname><given-names>S</given-names></name><name><surname>Boulad</surname><given-names>F</given-names></name><name><surname>Poignard</surname><given-names>P</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Pereyra</surname><given-names>F</given-names></name><name><surname>Ho</surname><given-names>DD</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Chait</surname><given-names>BT</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding</article-title><source>Science</source><volume>333</volume><fpage>1633</fpage><lpage>1637</lpage><pub-id pub-id-type="doi">10.1126/science.1207227</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Schrödinger</surname><given-names>LLC</given-names></name></person-group><year iso-8601-date="2011">2011</year><source>The PyMOL Molecular Graphics System</source><edition><italic>1.2r3pre</italic></edition></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinha</surname><given-names>N</given-names></name><name><surname>Smith-Gill</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Molecular dynamics simulation of a high-affinity antibody-protein complex: the binding site is a mosaic of locally flexible and preorganized rigid regions</article-title><source>Cell Biochemistry and Biophysics</source><volume>43</volume><fpage>253</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1385/CBB:43:2:253</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorpe</surname><given-names>IF</given-names></name><name><surname>Brooks</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Molecular evolution of affinity and flexibility in the immune system</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>104</volume><fpage>8821</fpage><lpage>8826</lpage><pub-id pub-id-type="doi">10.1073/pnas.0610064104</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verdaguer</surname><given-names>N</given-names></name><name><surname>Mateu</surname><given-names>MG</given-names></name><name><surname>Bravo</surname><given-names>J</given-names></name><name><surname>Domingo</surname><given-names>E</given-names></name><name><surname>Fita</surname><given-names>I</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Induced pocket to accommodate the cell attachment Arg-Gly-Asp motif in a neutralizing antibody against foot-and-mouth-disease virus</article-title><source>Journal of Molecular Biology</source><volume>256</volume><fpage>364</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1996.0092</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Victora</surname><given-names>GD</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Germinal centers</article-title><source>Annual Review of Immunology</source><volume>30</volume><fpage>429</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-020711-075032</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wedemayer</surname><given-names>GJ</given-names></name><name><surname>Patten</surname><given-names>PA</given-names></name><name><surname>Wang</surname><given-names>LH</given-names></name><name><surname>Schultz</surname><given-names>PG</given-names></name><name><surname>Stevens</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Structural Insights into the Evolution of an Antibody Combining Site</article-title><source>Science</source><volume>276</volume><fpage>1665</fpage><lpage>1669</lpage><pub-id pub-id-type="doi">10.1126/science.276.5319.1665</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>AP</given-names></name><name><surname>Diskin</surname><given-names>R</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>109</volume><elocation-id>E2083</elocation-id><lpage>E2090</lpage><pub-id pub-id-type="doi">10.1073/pnas.1208984109</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>AP</given-names></name><name><surname>Scharf</surname><given-names>L</given-names></name><name><surname>Scheid</surname><given-names>JF</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Structural insights on the role of antibodies in HIV-1 vaccine and therapy</article-title><source>Cell</source><volume>156</volume><fpage>633</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.01.052</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>ZY</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Hogerkorp</surname><given-names>CM</given-names></name><name><surname>Schief</surname><given-names>WR</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Schmidt</surname><given-names>SD</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Longo</surname><given-names>NS</given-names></name><name><surname>McKee</surname><given-names>K</given-names></name><name><surname>O'Dell</surname><given-names>S</given-names></name><name><surname>Louder</surname><given-names>MK</given-names></name><name><surname>Wycuff</surname><given-names>DL</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Nason</surname><given-names>M</given-names></name><name><surname>Doria-Rose</surname><given-names>N</given-names></name><name><surname>Connors</surname><given-names>M</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name><name><surname>Roederer</surname><given-names>M</given-names></name><name><surname>Wyatt</surname><given-names>RT</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1</article-title><source>Science</source><volume>329</volume><fpage>856</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1126/science.1187659</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Georgiev</surname><given-names>I</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Longo</surname><given-names>NS</given-names></name><name><surname>Louder</surname><given-names>M</given-names></name><name><surname>McKee</surname><given-names>K</given-names></name><name><surname>O'Dell</surname><given-names>S</given-names></name><name><surname>Perfetto</surname><given-names>S</given-names></name><name><surname>Schmidt</surname><given-names>SD</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>ZY</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Bonsignori</surname><given-names>M</given-names></name><name><surname>Crump</surname><given-names>JA</given-names></name><name><surname>Kapiga</surname><given-names>SH</given-names></name><name><surname>Sam</surname><given-names>NE</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Simek</surname><given-names>M</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Koff</surname><given-names>WC</given-names></name><name><surname>Doria-Rose</surname><given-names>NA</given-names></name><name><surname>Connors</surname><given-names>M</given-names></name><name><surname>Mullikin</surname><given-names>JC</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name><name><surname>Roederer</surname><given-names>M</given-names></name><name><surname>Shapiro</surname><given-names>L</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><collab>NISC Comparative Sequencing Program</collab></person-group><year iso-8601-date="2011">2011</year><article-title>Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing</article-title><source>Science</source><volume>333</volume><fpage>1593</fpage><lpage>1602</lpage><pub-id pub-id-type="doi">10.1126/science.1207532</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Georgiev</surname><given-names>I</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>ZY</given-names></name><name><surname>Dai</surname><given-names>K</given-names></name><name><surname>Finzi</surname><given-names>A</given-names></name><name><surname>Kwon</surname><given-names>YD</given-names></name><name><surname>Scheid</surname><given-names>JF</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Sodroski</surname><given-names>J</given-names></name><name><surname>Shapiro</surname><given-names>L</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01</article-title><source>Science</source><volume>329</volume><fpage>811</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1126/science.1192819</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Moquin</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Acharya</surname><given-names>P</given-names></name><name><surname>Georgiev</surname><given-names>IS</given-names></name><name><surname>Altae-Tran</surname><given-names>HR</given-names></name><name><surname>Chuang</surname><given-names>GY</given-names></name><name><surname>Joyce</surname><given-names>MG</given-names></name><name><surname>Kwon</surname><given-names>YD</given-names></name><name><surname>Longo</surname><given-names>NS</given-names></name><name><surname>Louder</surname><given-names>MK</given-names></name><name><surname>Luongo</surname><given-names>T</given-names></name><name><surname>McKee</surname><given-names>K</given-names></name><name><surname>Schramm</surname><given-names>CA</given-names></name><name><surname>Skinner</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zheng</surname><given-names>A</given-names></name><name><surname>Bonsignori</surname><given-names>M</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Scheid</surname><given-names>JF</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Simek</surname><given-names>M</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Koff</surname><given-names>WC</given-names></name><name><surname>Mullikin</surname><given-names>JC</given-names></name><name><surname>Connors</surname><given-names>M</given-names></name><name><surname>Shapiro</surname><given-names>L</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name><collab>NISC Comparative Sequencing Program</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies</article-title><source>Immunity</source><volume>39</volume><fpage>245</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.04.012</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Lynch</surname><given-names>RM</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Acharya</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Doria-Rose</surname><given-names>NA</given-names></name><name><surname>Joyce</surname><given-names>MG</given-names></name><name><surname>Lingwood</surname><given-names>D</given-names></name><name><surname>Soto</surname><given-names>C</given-names></name><name><surname>Bailer</surname><given-names>RT</given-names></name><name><surname>Ernandes</surname><given-names>MJ</given-names></name><name><surname>Kong</surname><given-names>R</given-names></name><name><surname>Longo</surname><given-names>NS</given-names></name><name><surname>Louder</surname><given-names>MK</given-names></name><name><surname>McKee</surname><given-names>K</given-names></name><name><surname>O’Dell</surname><given-names>S</given-names></name><name><surname>Schmidt</surname><given-names>SD</given-names></name><name><surname>Tran</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Druz</surname><given-names>A</given-names></name><name><surname>Luongo</surname><given-names>TS</given-names></name><name><surname>Moquin</surname><given-names>S</given-names></name><name><surname>Srivatsan</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>A</given-names></name><name><surname>Pancera</surname><given-names>M</given-names></name><name><surname>Kirys</surname><given-names>T</given-names></name><name><surname>Georgiev</surname><given-names>IS</given-names></name><name><surname>Gindin</surname><given-names>T</given-names></name><name><surname>Peng</surname><given-names>H-P</given-names></name><name><surname>Yang</surname><given-names>A-S</given-names></name><name><surname>Mullikin</surname><given-names>JC</given-names></name><name><surname>Gray</surname><given-names>MD</given-names></name><name><surname>Stamatatos</surname><given-names>L</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Koff</surname><given-names>WC</given-names></name><name><surname>Cohen</surname><given-names>MS</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name><name><surname>Casazza</surname><given-names>JP</given-names></name><name><surname>Connors</surname><given-names>M</given-names></name><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Sattentau</surname><given-names>QJ</given-names></name><name><surname>Weiss</surname><given-names>RA</given-names></name><name><surname>West</surname><given-names>AP</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Scheid</surname><given-names>JF</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Shapiro</surname><given-names>L</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors</article-title><source>Cell</source><volume>161</volume><fpage>1280</fpage><lpage>1292</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.05.007</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.13783.027</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Chakraborty</surname><given-names>Arup K</given-names></name><role>Reviewing editor</role><aff id="aff6"><institution>Massachusetts Institute of Technology</institution>, <country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your work entitled &quot;Structural basis for germline antibody recognition of gp120-based HIV-1 immunogens&quot; for consideration by <italic>eLife</italic>. Your article has been favorably evaluated by three reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation was overseen by Tadatsugu Taniguchi as Senior editor.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. Please find below the general and specific comments.</p><p>The induction of bnAbs against HIV by vaccination will undoubtedly require the activation of their germline precursors. The design of such immunogens is a major problem. In this work, the interactions made between germline VRC01-class Abs and gp120 constructs were studied. Five new crystal structures were solved: one unliganded germline VRC01-class Ab, one unliganded gp120 that has been modified for germline Ab binding, two complex structures of GL VRC01-class Abs bound to the engineered gp120 core and one complex structure of a VRC01-class bnAb bound to the engineered gp120 core. An in depth comparison between these five structures as well as previously solved structures is carried out to evaluate conformational changes in the GL Abs and bnAbs, gp120/Ab contacts, buried surface area, angles of approach, glycan interactions, and electrostatics.</p><p>While, as noted by the authors, much of the analysis of angle of approach, BSA, conserved contacts and preformed conformation of the Abs can already be found in West/Bjorkman (PNAS, 2012), Diskin/Bjorkman (J Exp Med, 2013), Jardine/Schief (Science, 2013) and Scharf/Diskin (PNAS, 2013), since structures of a complex between a fully germline VRCO1-class Ab and a complex gp120 core were not available, the addition of the five crystal structures, especially the 426c bound structures, is valuable to the field. Moreover, many of the findings derived from the structures are significant. However, the following points need to be addressed in a revised manuscript.</p><p>1) Comparison of &quot;binding mode&quot; as reported by translation distance and rotation angle: this discussion is interesting but incomplete and requires further clarification.</p><p>The wire diagrams in <xref ref-type="fig" rid="fig7">Figure 7A</xref> imply that the portions of the antibodies proximal to gp120 are much better aligned than the distal portions. This begs the question: Might the distance/angle differences in <xref ref-type="fig" rid="fig7">Figure 7B</xref> be due to protein flexibility in the Fab domains accommodating differences in crystal packing? This point should be carefully examined and discussed to support the relevance of the measurements to vaccine design or therapeutic antibody design.</p><p>The true target of these antibodies is a native trimer that may restrict the translation distance and angle of approach more severely than the core-gp120s in the crystal structures analyzed here. Because these antibodies are broadly neutralizing, we already know that they can bind native trimers of diverse strains. Are the authors confident that the variations in distance and angle reported here would be reproduced if crystal structures were solved with the same antibodies in complex with native-like trimers? A key uncertainty in this regard is caused by the bridging sheet, an important aspect of the VRC01-class interaction with gp120 that has been shown to be in very different conformations in core-gp120 structures (complexed with CD4 or VRC01-class bnAbs) as compared to native-like trimer structures (Lyumkis et al. Science 2013, <xref ref-type="fig" rid="fig5">Figure 5A</xref>). Further uncertainty comes from the V2 loop that is known to restrict access to the CD4 binding site on the trimer, yet is absent from the structures analyzed here. Finally, the many glycans around the CD4 binding site on the trimer may restrict the translation distance and measured angle. The authors should attempt to use the published structures of the BG505 SOSIP native-like trimer and other native-like trimers to assess the relevance of their distance/angle measurements on core-gp120 to the interaction of VRC01-class bnAbs with native-like trimers.</p><p>The authors have computed translation distance and rotation angle only for a subset of the VRC01-class bnAbs for which high resolution structures are available. This incomplete analysis means that the distance/angle distribution for VRC01-class bnAbs interacting with core-gp120 might be broader (or narrower) than currently represented in <xref ref-type="fig" rid="fig7">Figure 7B</xref>. The incomplete analysis leaves open the possibility that the distance/angle values for the TM1 and TM4 structures may not be as divergent from the previously known structures as implied by <xref ref-type="fig" rid="fig7">Figure 7B</xref>. The authors should include analysis of several (if not all) currently available structures of VRC01-class bnAbs in complex with core-gp120.</p><p>The authors should comment on the fact that the eOD is a more minimal antigen than 426c yet it appears to better preserve the distance/angle of the VRC01-class interaction (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). Can the authors discern the structural reason why 426c supports a more unusual distance/angle interaction mode even though it contains the inner domain and bridging sheet that are absent from eOD? This type of analysis could help guide further immunogen design.</p><p>The authors have computed translation distance and rotation angle for one antibody (3BNC117MAT) crystallized with three different gp120 molecules, but they should provide some discussion of the variation if any in the distance/angle values among these three structures. This would provide a useful reference for the effects of gp120 strain variation and crystal packing on the distance/angle values that are being measured.</p><p>2) The discussion of how the electrostatics of the VRC01-class Abs' interaction is changed by affinity maturation is very interesting. The reason offered by the authors is that this helps binding to the glycans. But, the arguments pertinent to this issue in the Discussion – are a bit confusing. At the start of the fifth paragraph it is stated that interactions with glycans are facilitated by the change in electrostatic potential. Later in that paragraph it is stated that this helps avoiding interactions with the glycan. Some rewording may be appropriate. Perhaps, the authors mean to say that somatic hypermutation on the LC has two objectives-the main one being to avoid clashes with the N276 glycan that will block binding, and secondly to make additional contacts to the glycan?</p><p>Even though this finding is of interest, the discussion of this being related to interactions with complex glycans with negatively charged sialic acids needs to be tempered. The degree to which the N276 glycan or other glycans near the VRC01-class epitope are complex type rather than high mannose is not well understood. The existing data on glycosylation profiles of HIV Env are incomplete as they were largely measured on gp120 molecules rather than native-like trimers.</p><p>3) The discussion of lock-and-key versus induced-fit binding mechanisms is simplistic because in reality there is likely a continuum of binding mechanisms rather than only two ways to bind. Could this discussion be nuanced?</p><p>4) The authors paint a picture that VRC01-class development involves &quot;lock-and-key&quot; germline Fab interaction with increasing flexibility during maturation. However, perhaps the Discussion should be modified to account for the following:</p><p>It is interesting that the 426c gp120 interaction with germline Fabs appears to involve little conformational change in the Fab. However, the authors seem to be making a leap when they attempt to contrast this finding with their previous observation that the CDRH3 of NIH45-46<sub>CHIM</sub> was disordered in the interaction with an &quot;unmodified&quot; gp120 is (Discussion, eighth paragraph). Could that difference not also be due to different crystal packing? Alternatively, could this be due to interaction with a different strain of gp120? Or due to the fact that one antibody is &quot;germline&quot; while the other is a chimera of &quot;germline&quot;-H with mature-L? It seems difficult to draw a strong conclusion from the contrast given. This is compounded by the fact that the CDRH3 makes little contact in most of the VRC01-class/core-gp120 crystal structures, hence whether the CDRH3 is ordered or not may not be highly important to the interaction.</p><p>To support the idea that VRC01-class maturation involves increasing flexibility, the authors then give the example (Discussion, eighth paragraph) of the Ala61<sub>HC</sub>Pro mutation in the 3BNC60/3BNC117 members of this class. However, the generality of this example is unclear. Do other members of the class exhibit similar features?</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.13783.028</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>[T]he following points need to be addressed in a revised manuscript. 1) Comparison of &quot;binding mode&quot; as reported by translation distance and rotation angle: this discussion is interesting but incomplete and requires further clarification.</italic> </p><p> <italic>The wire diagrams in <xref ref-type="fig" rid="fig7">Figure 7A</xref> imply that the portions of the antibodies proximal to gp120 are much better aligned than the distal portions.</italic> </p><p>The different Ab-gp120 complexes were compared by aligning their gp120 components. The closer alignment of the portions of the antibodies proximal to gp120 arises by necessity because differences would be expected to radiate out from the common point of alignment (the gp120).</p><p><italic>This begs the question: Might the distance/angle differences in <xref ref-type="fig" rid="fig7">Figure 7B</xref> be due to protein flexibility in the Fab domains accommodating differences in crystal packing? This point should be carefully examined and discussed to support the relevance of the measurements to vaccine design or therapeutic antibody design.</italic> </p><p>It is extremely unlikely that the interaction between the combining site of an antibody and its target antigen could be altered by crystal packing because these interactions result from intermolecular protein-protein contacts that span large surface areas, whereas crystal contacts bury relatively little surface area compared with interactions between partners in a protein-protein interaction (e.g., see J Janin, 1997, “Specific versus non-specific contacts in protein crystals” NSMB 4, 973-974). If the interaction between an antibody combining site and its antigen can be altered by crystal packing, then much of what has been learned from protein crystallography about antibody-antigen interactions (and protein-protein interactions in general) would be suspect.</p><p> <italic>The true target of these antibodies is a native trimer that may restrict the translation distance and angle of approach more severely than the core-gp120s in the crystal structures analyzed here. Because these antibodies are broadly neutralizing, we already know that they can bind native trimers of diverse strains. Are the authors confident that the variations in distance and angle reported here would be reproduced if crystal structures were solved with the same antibodies in complex with native-like trimers?</italic> </p><p>It’s not actually clear what the antigen target of germline antibodies is – it could be that shed gp120s bind to and activate germline BCRs. In any case, the 426c-based immunogens were designed to bind as gp120s, not as trimers, to germline antibodies. Indeed, the germline antibodies that were investigated in our study do not bind to native-like trimers or even to unaltered gp120s in general. Since currently available BG505 SOSIP trimer structures have no features that would prohibit the range of binding orientations we observed (see <xref ref-type="fig" rid="fig7">Figure 7C</xref> in revised manuscript), we would expect these variations to be reproduced in structures of corresponding BG505 SOSIP-Fab complexes.</p><p>The only published structures relevant to the reviewer’s question of whether the orientation observed for a mature VRC01-class Fab/gp120 complex is predictive of the orientation of the same Fab bound to a native-like trimer are the cryo-EM structure of PGV04 (also known as VRC-PG04) Fab bound to the BG505 SOSIP trimer (Lyumkis et al., 2013) and the structures of this Fab with gp120s (PDB codes 3SE9, 4I3S, and 4I3R). The PGV04/trimer structure yields a V<sub>H</sub> rotation and translation of 6.1° and 2.5 Å compared to the VRC01 reference, only modestly different from the values calculated for the PGV04/gp120 structure 3SE9 (5.6° and 0.8 Å).</p><p><italic>A key uncertainty in this regard is caused by the bridging sheet, an important aspect of the VRC01-class interaction with gp120 that has been shown to be in very different conformations in core-gp120 structures (complexed with CD4 or VRC01-class bnAbs) as compared to native-like trimer structures (Lyumkis et al.Science 2013, <xref ref-type="fig" rid="fig5">Figure 5A</xref>). Further uncertainty comes from the V2 loop that is known to restrict access to the CD4 binding site on the trimer, yet is absent from the structures analyzed here. Finally, the many glycans around the CD4 binding site on the trimer may restrict the translation distance and measured angle. The authors should attempt to use the published structures of the BG505 SOSIP native-like trimer and other native-like trimers to assess the relevance of their distance/angle measurements on core-gp120 to the interaction of VRC01-class bnAbs with native-like trimers.</italic> </p><p>Regarding the bridging sheet, while its conformation differs between Env trimers and gp120 monomers, and some CD4bs Abs make close contacts with this region, for the VRC01-like bNAbs, the bridging sheet in the trimer is mostly out of range for direct contacts. This is indicated in the Lyumkis et al., 2013, <xref ref-type="fig" rid="fig5">Figure 5C</xref> legend, which refers to “minimal clashes with PGV04” [a VRC01-like bNAb], as compared with predicted clashes with non-VRC01-class CD4bs bNAbs. Alignment of the 3BNC60<sub>GL</sub> Fab-426c gp120 structure with the Env trimer of PDB entry 5CEZ indicates the closest distance between the Fab and the bridging sheet strands that have different topology in the trimer (beta2-beta3) is about 9 Å (Fab HC Ser75 to Env residue 198).</p><p>The reviewers point out that the V2 loop and glycans restrict access to the CD4 binding site on the trimer. However, the V1V2 and V3 loops, as well as some of the N-glycans around the CD4 binding site, were removed from the 426c-based gp120 immunogens in order to permit them to engage germline versions of VRC01-class bNAb B cell receptors. The presence of these features on native-like Env trimers likely explains why they are not recognized by germline versions of CD4-binding site bNAbs (e.g., McGuire et al., 2016, Nature Comm) shows that 3BNC60<sub>GL</sub> does not bind the 426c gp120 when the variable loops are present).</p><p>Nevertheless, we can model a germline Fab onto a BG505 SOSIP structure to see if the altered orientation sterically clashes with adjacent subunits in the trimer. This modeling exercise suggests that the different orientation of the 3BNC60<sub>GL</sub> Fab with respect to gp120 moves it away from the adjacent gp120 subunit, suggesting this orientation would be sterically compatible when binding to Env trimer (shown in <xref ref-type="fig" rid="fig7">Figure 7C, a</xref> new figure in the revised manuscript). In this model the closest Cα–Cα distance between the 3BNC60<sub>GL</sub> Fab and the adjacent gp120 is about 6.5 Å.</p><p>Modeling clashes with glycans present in any trimer-Fab (or gp120-Fab) molecular structure would offer limited insight into the actual steric hindrance that antibodies have to accommodate. With the exception of the N-acetyl glucosamine residue attached directly to the Asn of an <italic>N</italic>-linked glycosylation site, glycans have no rigid orientation or position. Furthermore, a glycan conformation observed in a high resolution structure is due to contacts it makes with other molecules as this conformation is only one of many conformations accessible to that glycan (e.g., the Asn276<sub>gp120</sub> glycan is ordered in the structure of a VRC01-class Fab/gp120 complex (45-46m2/93TH057; Diskin et al., 2013) and in structures of 8ANC195 (not a CD4bs bNAb) bound to gp120 or to BG505 SOSIP (Scharf et al., 2014; 2015), but it occupies different positions when Env is bound to the CD4bs bNAb versus when it is bound to the 8ANC195 Fab).</p><p> <italic>The authors have computed translation distance and rotation angle only for a subset of the VRC01-class bnAbs for which high resolution structures are available. This incomplete analysis means that the distance/angle distribution for VRC01-class bnAbs interacting with core-gp120 might be broader (or narrower) than currently represented in <xref ref-type="fig" rid="fig7">Figure 7B</xref>. The incomplete analysis leaves open the possibility that the distance/angle values for the TM1 and TM4 structures may not be as divergent from the previously known structures as implied by <xref ref-type="fig" rid="fig7">Figure 7B</xref>. The authors should include analysis of several (if not all) currently available structures of VRC01-class bnAbs in complex with core-gp120.</italic> </p><p>This point is addressed in our explanation of the question below.</p><p> <italic>The authors should comment on the fact that the eOD is a more minimal antigen than 426c yet it appears to better preserve the distance/angle of the VRC01-class interaction (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). Can the authors discern the structural reason why 426c supports a more unusual distance/angle interaction mode even though it contains the inner domain and bridging sheet that are absent from eOD? This type of analysis could help guide further immunogen design.</italic> </p><p>The original <xref ref-type="fig" rid="fig7">Figure 7B</xref> included VRC01-class bNAbs from 8 of the 9 published independent clonal families of this class of bNAb. To provide a more comprehensive analysis, we have now included all cases with published structures, as well as including alignment results for all bNAb/Env complexes within the asymmetric unit of each crystal structure. The new version of <xref ref-type="fig" rid="fig7">Figure 7B</xref> includes 25 mature VRC01-class antibody alignments, as compared with 9 in the original version.</p><p>Unfortunately it is difficult to discern a structural reason for the differences in orientation in the eOD and 426c.TM△V1-3 complexes due to the extensive interfaces and large numbers of contacts.</p><p> <italic>The authors have computed translation distance and rotation angle for one antibody (3BNC117MAT) crystallized with three different gp120 molecules, but they should provide some discussion of the variation if any in the distance/angle values among these three structures. This would provide a useful reference for the effects of gp120 strain variation and crystal packing on the distance/angle values that are being measured.</italic> </p><p>The more comprehensive analysis now presented in <xref ref-type="fig" rid="fig7">Figure 7B</xref> (and detailed in <xref ref-type="supplementary-material" rid="SD1-data">Figure 7B—source data 1</xref>) shows the distance/angles values are consistent among individual complexes in the asymmetric unit (which are subject to different crystal packing interactions). The analysis also shows consistency among complexes crystallized with different gp120s and between mutants/clonal variants.</p><p> <italic>2) The discussion of how the electrostatics of the VRC01-class Abs' interaction is changed by affinity maturation is very interesting. The reason offered by the authors is that this helps binding to the glycans. But, the arguments pertinent to this issue in the Discussion are a bit confusing. At the start of the fifth paragraph it is stated that interactions with glycans are facilitated by the change in electrostatic potential. Later in that paragraph it is stated that this helps avoiding interactions with the glycan. Some rewording may be appropriate. Perhaps, the authors mean to say that somatic hypermutation on the LC has two objectives-the main one being to avoid clashes with the N276 glycan that will block binding, and secondly to make additional contacts to the glycan?</italic> </p><p>Thank you for pointing out these points of confusion in the original manuscript. The revised paper states that the increased electropositivity could be part of a multi-pronged approach of the humoral immune response against the CD4 binding site of HIV-1 for accommodating and/or for avoiding the complex <italic>N</italic>-linked Env glycan attached to Asn276<sub>gp120</sub>.</p><p><italic>Even though this finding is of interest, the discussion of this being related to interactions with complex glycans with negatively charged sialic acids needs to be tempered. The degree to which the N276 glycan or other glycans near the VRC01-class epitope are complex type rather than high mannose is not well understood. The existing data on glycosylation profiles of HIV Env are incomplete as they were largely measured on gp120 molecules rather than native-like trimers.</italic> </p><p>We agree and have revised the discussion of the potential interactions with negatively charged sialic acids. Regarding glycosylation profiles, we added a citation to a recent manuscript from Max Crispin’s laboratory (Behrens et al., 2016, in press) in which they have determined the site-specific glycan profile of BG505 SOSIP.664, a native-like trimer.</p><p> <italic>3) The discussion of lock-and-key versus induced-fit binding mechanisms is simplistic because in reality there is likely a continuum of binding mechanisms rather than only two ways to bind. Could this discussion be nuanced?</italic> The reviewers make an important point. We have revised the discussion of these antibody binding mechanisms to make the points in a more nuanced manner.</p><p><italic>4) The authors paint a picture that VRC01-class development involves &quot;lock-and-key&quot; germline Fab interaction with increasing flexibility during maturation. However, perhaps the Discussion should be modified to account for the following:</italic> </p><p> <italic>It is interesting that the 426c gp120 interaction with germline Fabs appears to involve little conformational change in the Fab. However, the authors seem to be making a leap when they attempt to contrast this finding with their previous observation that the CDRH3 of NIH45-46<sub>CHIM</sub> was disordered in the interaction with an &quot;unmodified&quot; gp120 is (Discussion, eighth paragraph). Could that difference not also be due to different crystal packing?</italic> </p><p>Neither the CDRH3 loop of the NIH45-46<sub>CHIM</sub>/93TH057 gp120 complex nor the CDRH3 loop of the NIH45-46<sub>GL</sub>/426c.TM1△V1-3 gp120 complex structure are involved in crystal packing interactions (see <xref ref-type="fig" rid="fig9">Author response image 1</xref>).<fig id="fig9" position="float"><object-id pub-id-type="doi">10.7554/eLife.13783.016</object-id><label>Author response image 1.</label><caption><title>CDR3<sub>HC</sub> positions in NIH45-46<sub>CHIM</sub>/93TH057 gp120 (left) and NIH45-46<sub>GL</sub>/426c.TM1△V1-3 gp120 (right) complexes relative to symmetry mates (different views shown for clarity).</title><p>One complex of gp120 (grey) with antibody V<sub>H</sub> (pink) and V<sub>L</sub> (light pink) is shown with the nearest two symmetry mates (blue and green). The disordered region of NIH45-46<sub>CHIM</sub> CDRH3 is indicated by a dashed line. The CDRH3 loop is not engaged in crystal packing interactions in either complex.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.13783.016">http://dx.doi.org/10.7554/eLife.13783.016</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-13783-resp-fig1-v1"/></fig></p><p><italic>Alternatively, could this be due to interaction with a different strain of gp120? Or due to the fact that one antibody is &quot;germline&quot; while the other is a chimera of &quot;germline&quot;-H with mature-L?</italic> </p><p>Either of these reasons could account for the difference. Since a germline HC/germline LC NIH45-46 Fab did not bind to 93TH057 gp120, while the germline HC/mature LC chimeric Fab did, it seems likely that this difference is due to the inclusion of the mature LC.</p><p><italic>It seems difficult to draw a strong conclusion from the contrast given. This is compounded by the fact that the CDRH3 makes little contact in most of the VRC01-class/core-gp120 crystal structures, hence whether the CDRH3 is ordered or not may not be highly important to the interaction.</italic> </p><p>Please see Table S4 from Diskin et al., 2011, Science in which we compared the surface areas buried on different structural elements of NIH45-46 and VRC01. The surface areas buried on CDR3 represent 28% (NIH45-46) and 13% (VRC01) of the total surface area buried on the Fab by gp120. Thus although VRC01-class bNAbs do not fall in the CDRH3-dominated class of CD4-binding site antibodies (as defined by Zhou et al., 2015, Cell), the CDRH3 loops make important contacts to gp120 that are critical for their interactions.</p><p> <italic>To support the idea that VRC01-class maturation involves increasing flexibility, the authors then give the example (Discussion, eighth paragraph) of the Ala61<sub>HC</sub>Pro mutation in the 3BNC60/3BNC117 members of this class. However, the generality of this example is unclear. Do other members of the class exhibit similar features?</italic></p><p>The 3BNC clonal family (3BNC60/3BNC117) is the only set of VRC01-class antibodies that includes the Ala61Pro somatic hypermutation. This substitution nonetheless represents an example of increased flexibility during antibody maturation.</p></body></sub-article></article>